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Most gram-negative organisms require lipopolysaccharide and its membrane anchor, lipid 
A, for growth and survival. Also known as endotoxin, lipid A is synthesized via a nine-
step enzymatic process, culminating in a conserved hexa-acylated, bis-phosphorylated 
disaccharide of glucosamine. This framework is often altered by condition- or species-
specific lipid A modifications, which change the biochemical properties of the molecule 
in response to and to defend against environmental stress signals. Here, we expound on 
two stories in different gram-negative organisms, both involving novel or unanticipated 
biochemistry that impacts lipid A structure. First, the missing acyltransferase in the 
Epsilonproteobacterium Helicobacter pylori lipid A biosynthesis pathway is identified. 
This enzyme transfers a secondary acyl chain to the 3'-linked primary acyl chain of lipid 
A like E. coli LpxM, but shares almost no sequence similarity with the E. 
coli acyltransferase. It is reannotated as LpxJ and demonstrated to possess an 
unprecedented ability to act before the 2'-secondary acyltransferase, LpxL, as well as 
the 3-deoxy-D-manno-octulosonic acid transferase, KdtA. LpxJ is one member of a large 
class of acyltransferases found in a diverse range of organisms that lack an E. coli LpxM 
homolog, suggesting that LpxJ participates in lipid A biosynthesis in place of an LpxM 
homolog. The second story focuses on regulation of modifications to endotoxin structure 
that occur after the conserved biosynthesis pathway. E. coli pmrD is shown to be required 
for PmrAB-dependent lipid A modifications in conditions that exclusively activate 
PhoPQ; this result proves that PmrD connects PhoPQ and PmrAB despite previous 
reports that it is an inactive connector in this organism. Further, RNA sequencing and 
 vii 
polymyxin B survival assays solidify the role of E. coli pmrD in influencing expression 
of pmrA and its target genes and promoting survival during exposure to cationic 
antimicrobial peptides. Notably, the presence of an unknown factor or system capable of 
activating pmrD to promote lipid A modification in the absence of the PhoPQ system is 
also revealed. In all, the findings presented here expand our understanding of alternative 
approaches to lipid A biosynthesis and the complex systems that regulate modifications 
of this dynamic molecule.   
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Chapter 1: Introduction 
1.1 LIPOPOLYSACCHARIDE AND LIPID A BIOSYNTHESIS 
1.1.1 The Gram-negative cell envelope 
In gram-negative bacteria, the cell envelope is distinguished by the presence of an 
outer membrane, a complex structure that acts as a dynamic canvas for response to, 
interaction with, and protection against a rapidly changing environment. The outer 
membrane is made of an inner leaflet of phospholipids and an outer leaflet populated by 
the bioactive macromolecule lipopolysaccharide (LPS) (Fig 1.1) (1). LPS is anchored to 
the membrane via its lipid A domain, an acylated disaccharide of glucosamine also 
referred to as endotoxin. Attached to the lipid A is a set of core sugars, which typically 
includes two 3-deoxy-D-manno-octulosonic acid (Kdo) residues, heptose, and various 
hexose sugars. Beyond the core, many gram-negatives also have a long chain of repeating 
oligosaccharides known as the O-antigen, which shows extensive variation in sugar 
composition and residue number across this class of bacteria (2).  
The prototypical lipid A structure is that produced by the well-studied enteric 
bacterium Escherichia coli. Consisting of a β(1,6)-linked disaccharide of glucosamine 
that is bis-phosphorylated and hexa-acylated, this specific structure is the strongest 
known agonist for the Toll-like receptor 4/myeloid differentiation factor-2 (TLR4/MD2) 
complex present on circulating immune cells (2–4). During infection, LPS is extracted 
from the outer bacterial membrane or picked up in aggregates by LPS-binding protein 
and delivered to cluster of differentiation 14 (CD14) and TLR4/MD2 at the host cell 
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surface (5, 6). LPS establishes a highly specific interaction with TLR4/MD2 via its lipid 
A domain, which nestles five of its acyl chains into a large hydrophobic pocket within the 
MD2 co-receptor and dangles the sixth outside to interact with TLR4 (7). LPS binding 
induces dimerization of TLR4-MD2 complexes, which initiates intracellular signaling 
cascades that lead to production of pro-inflammatory cytokines necessary for clearance of 
infection. However, excessive activation of these pathways leads to vascular instability, 
multiple organ failure, and potential death for an infected host (8, 9). As such, lipid A is 
regarded as a major virulence factor for many gram-negative organisms. The lipid A 
domain can also be modified by enzymes that add and/or remove various chemical 
groups, which can affect the TLR4 response. Some organisms have evolved complex 
regulated modification cascades that create a mildly- or non-stimulatory final lipid A 
structure, allowing for evasion of immune recognition and survival within the host. 
Several such examples will be discussed in a later section.  
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Figure 1.1: Gram-negative bacterial cell envelope 
Gram-negative bacteria possess inner and outer lipid bilayer membranes separated by a 
periplasmic space containing a thin layer of peptidoglycan. The outer membrane is 
composed half of phospholipids (inner leaflet) and half of lipopolysaccharide (outer 
leaflet), while the inner membrane is predominantly phospholipids. β-barrel proteins 
punctuate the outer membrane while α-helical proteins are found at the inner membrane. 
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1.1.2 The Raetz pathway 
 The vast majority of gram-negative organisms require lipid A for growth and 
survival. This crucial membrane component is built at the cytosolic leaflet of the inner 
membrane by the successive activities of nine well-conserved Lpx enzymes of the Raetz 
pathway, first described in E. coli (Fig 1.2) (2). Briefly, the process begins with the 
activity of LpxA, which adds an acyl chain to the activated nucleotide sugar donor, 
uridine diphosphate N-acetylglucosamine (10).  In the following early steps of the 
pathway, this substructure is deacetylated by metalloamidase LpxC, further acylated by 
LpxD, and cleaved at the pyrophosphate bond by LpxH or LpxI to form the lipid X 
species (11–14). Next, the defining β(1,6)-glycosidic linkage of lipid A is formed by 
glycosyltransferase LpxB, generating disaccharide 1-phosphate, which is then 4′-
phosphorylated by LpxK to form lipid IVA (15, 16). The late steps include transfer of two 
Kdo sugars to the distal glucosamine by WaaA (KdtA), and finally addition of 2′- and 3′-
secondary acyl chains by LpxL and LpxM, respectively (17–19). The Raetz pathway 
culminates in formation of hexa-acylated Kdo2-lipid A, which is then united with core 
and O-antigen sugars and transported across membrane compartments for display at the 
outer leaflet.   
 While many gram-negatives encode homologs to the E. coli Lpx enzymes for 
completion of their respective Raetz pathways, some organisms use enzymes with unique 
sequence and/or substrate specificity to build lipid A. These differences can be as subtle 
as hydrocarbon ruler length preference in the enzyme active site, or as significant as a 
total lack of sequence identity with the corresponding E. coli Lpx enzyme.   
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Figure 1.2: The E. coli Raetz pathway of lipid A biosynthesis 
Lipid A is constructed in a nine-step conserved enzymatic pathway by the Lpx enzymes, 
shown in red. The final product of the Raetz pathway in E. coli is a β(1,6)-linked 
disaccharide of glucosamine that is bis-phosphorylated and hexa-acylated.  
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 For example, while Pseudomonas aeruginosa and Helicobacter pylori both 
encode homologs of E. coli LpxA, each has a hydrocarbon ruler with different acyl chain 
length demands: E. coli LpxA requires a 14-carbon chain, P. aeruginosa a 10-carbon 
chain, and H. pylori a 16-carbon chain (20–22). These enzymatic preferences are 
reflected directly in the lipid A frameworks produced by each organism.  
 Further, E. coli and many other gram-negatives use LpxH to generate lipid X 
from UDP-diacyl glucosamine. Other organisms including members of the α-
proteobacteria, however, encode LpxI, a protein unrelated by sequence to and employing 
a unique catalytic mechanism from LpxH (13). Specifically, LpxH orchestrates attack of 
the α-phosphate of UDP-diacyl glucosamine while LpxI instead targets the β-phosphate 
(12, 13).  
 E. coli can also depart from the conserved Raetz pathway in certain conditions. 
When growth temperature is shifted to 12°C, incorporation of palmitoleate (C16:1) into 
the lipid A increases due to the activity of cold-shock acyltransferase LpxP (23). A 
homolog of late acyltransferase LpxL, LpxP uses Kdo2-lipid IVA as substrate, transferring 
a palmitoleate to the same position on the lipid A molecule as LpxL, the hydroxyl group 
of the 3′-primary acyl (23). At this sub-normal growth temperature, LpxP is 
transcriptionally upregulated and the enzyme performs acyltransfer to this position in 
place of LpxL. This divergence from the typical late Raetz pathway is an adaptation 
thought to maintain membrane fluidity at a lower temperature, as well as increasing 
barrier function against antibiotics (23, 24)  
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 In this work, another Raetz pathway enzymatic anomaly is identified and 
characterized, this time in H. pylori and other ε-proteobacteria. This enzyme, from hereon 
referred to as LpxJ, transfers the secondary acyl chain to the 3′-linked primary acyl chain 
of H. pylori lipid A, similarly to LpxM in E. coli. However, LpxJ exhibits flexibility in 
substrate specificity not observed with LpxM, performing acyltransfer regardless of the 
presence of Kdo sugars and the ability to do so before the H. pylori LpxL homolog (22, 
25). This enzyme, discussed in detail in Chapter 2, represents an extensive previously 
uncharacterized family of lipid A late acyltransferases that may allow for multiple routes 
at the end of the lipid A biosynthesis pathway.  
1.2 MODIFICATION OF LIPID A 
A sampling of outer leaflets across multiple gram-negatives reveals considerable 
diversity in terms of the precise chemical composition of surface-presented lipid A. 
Variability in lipid A structure occurs due to the activity of enzymes that add or remove 
assorted chemical groups, sometimes resulting in a final structure that only vaguely 
resembles the unmodified Raetz pathway output product. Such modifications occur 
constitutively in some organisms or may be strictly regulated to promote survival in 
certain conditions.  
1.2.1 Constitutive modification of Helicobacter pylori lipid A 
 A classic example of an organism with extensively modified lipid A is H. pylori. 
This adapted gastric pathogen colonizes half the world’s population and can cause life-
long infection in the form of peptic ulcers and gastric cancer (26). During transport to the 
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outer membrane, its lipid A becomes the substrate for five constitutive modification 
enzymes that dramatically alter its structure and biochemical properties (Fig 1.3). First, 
the 1-phosphate group is removed by LpxE and a phosphoethanolamine (pEtN) is added 
in its place by EptA (27). Next, the terminal Kdo sugar added by WaaA is removed by 
the two-protein Kdo-hydrolase complex, Kdo H1/H2, leaving a single Kdo at the inner 
core (28). The 4ʹ′-phosphate group is then removed by LpxF, just before the lipid A 
molecule is joined with the core sugars and O-antigen to form a mature LPS molecule 
(29). After transport to the outer leaflet of the outer membrane, the lipid A moiety 
undergoes a final modification: removal of the 3ʹ′-linked acyl chains by LpxR, producing 
the final tetra-acylated lipid A structure characteristic of the H. pylori outer membrane 
(Fig 1.3, inset)(22). 
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Figure 1.3: Modification of H. pylori lipid A generates its unique structure 
Kdo2-lipid A is flipped to the periplasmic leaflet of the inner membrane by the conserved 
ABC-transporter MsbA. The 1-phosphate group is removed by LpxE, and a 
phosphorylethanolamine (pEtN) group is added in its place by EptA. The latter activity 
generates diacylglycerol (DAG), as phosphatidylethanolamine (PE) is likely the donor 
molecule for the pEtN group. Next, a two-protein Kdo-hydrolase complex, Kdo H1/H2, 
removes the terminal Kdo group. The last modification to occur before transport across 
the periplasm is the removal of the 4ʹ′-phosphate group by LpxF. Finally, the outer-
membrane β-barrel LpxR catalyzes removal of the 3′-linked acyl chains, generating the 
final lipid A structure in the outer membrane of H. pylori (inset). The core 
oligosaccharide and O-antigen chain with fucose additions are only shown in the inset for 
simplicity. 
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While drastically altering the physical construction of lipid A, these successive 
modifications also impact its interaction with the environment. For example, both the 
addition of EptA and removal of the 1- and 4ʹ′-phosphate groups reduce the net negative 
charge of each lipid A molecule and the outer membrane as a whole, thereby promoting 
resistance to cationic antimicrobial peptides (CAMPs) like polymyxin B, which will be 
discussed in further detail in a later section (30).  Importantly, alterations in acyl chain 
number and length, phosphate groups, and presence of polar functional groups can all 
impact the strength of the TLR4 response (8). The most iconic example of this concept is 
exhibited by the fact that hexa-acylated lipid A is the most potent known TLR4 agonist, 
while penta-acylated lipid A is 100-fold less active and tetra-acylated lipid A is actually 
antagonistic (7, 31). It is thought that under-acylation alters TLR4-reactivity because the 
acyl chains of lipid A have more space in which to move freely within the hydrophobic 
pocket of MD2, which could disrupt TLR4/MD2 dimerization (7). In the case of H. 
pylori, removal of the two 3ʹ′-acyl chains by LpxR is a major determinant in limiting the 
TLR4 response elicited by this organism’s lipid A. The two phosphate groups also 
contribute to the ligand-receptor interaction, as they contact positively charged residues 
within the TLR4/MD2 multimer (7). As such, deletion of one or both phosphate groups, 
as occurs with H. pylori lipid A, has been shown to greatly diminish endotoxic activity 
(32). Indeed, H. pylori surface-presented lipid A is up to 1000-times less 
immunostimulatory than that of E. coli as a result of this stringently adapted modification 
cascade (33–35). Ultimately, its lipid A structure helps this rugged enteric pathogen to 
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become a long-term resident of the human gut epithelium, striking a balance between 
causing disease and staying below the radar of the host immune system.  
1.2.2 Conditional lipid A modifications 
H. pylori is expertly adapted to life in the human gut epithelium, its only known 
reservoir. Its lipid A has evolved an optimal structure to flourish in this niche and the 
enzymes that modify it are constitutively expressed. This is not the case, however, in 
gram-negatives with complex life cycles or that experience rapidly changing 
environments. Common challenges that bacteria may encounter in the host or other 
surrounding environment include CAMPs, temperature fluctuations, changes in pH, and 
depletion of divalent cations.  
CAMPs, as the name would suggest, are short cationic amphipathic peptides with 
the ability to associate with and penetrate the negatively charged Gram-negative outer 
membrane. Produced by organisms from bacteria and fungi to animals, their modes of 
action include membrane permeabilization and targeting key processes like DNA, 
protein, and cell wall synthesis (36, 37). Modification of anionic outer membrane 
structures like lipid A can reduce the net negative charge of the membrane, minimizing 
interaction with CAMPs. This is crucial to promote survival in the human host where 
CAMPs are produced by cells at practically every point of bacterial entry and niche of 
infection: for example, skin keratinocytes, epithelial glands of the respiratory and 
genitourinary tract, epithelial cells in the crypts of the small intestine, and phagocytic 
cells of the innate immune system (38).  
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Survival in limited concentrations of divalent cations such as Mg2+ and Ca2+ is 
also problematic for gram-negative organisms. These metals create ionic bridges between 
neighboring negative lipid A molecules, which contribute significantly to outer 
membrane stability (39). When environmental divalent cations are low, the membrane 
becomes vulnerable in the absence of this crucial reinforcement, and the bacterium must 
respond in a manner that fortifies the membrane (40). Such responses can include various 
lipid A modifications that increase hydrophobicity and/or decrease negative charge of the 
molecule to stabilize lipid A within the LPS leaflet (39). Below are several examples of 
organisms that modify their lipid A to promote survival in difficult or changing 
conditions.  
1.2.2.1 Temperature changes acylation state of Yersinia pestis lipid A  
Yersinia pestis causes multiple forms of plague, which decimated the European 
population in the mid-1300s (41). In the environment, this pathogen typically passes 
between rodents and fleas, and can be transmitted to humans via both of these reservoirs 
(42). While proliferating in the flea gut, Yersinia experiences temperatures 10-15 degrees, 
lower (21-27°) than in a human host (37°C). It has been found that this host temperature 
switch induces a change in this organism’s lipid A; Y. pestis produces TLR4-stimulatory 
hexa-acylated lipid A inside the flea but antagonistic tetra-acylated lipid A in humans 
(Fig 1.4A)(43, 44). The immuno-evasive tetra-acylated structure is reminiscent of H. 
pylori lipid A, and is thought to allow undetected proliferation of Y. pestis in the human 
bloodstream during early infection (44, 45). This lipid A phenotypic adaptation appears 
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to be critical in pathogenesis, as a mutant strain that can only produce hexa-acylated lipid 
A is avirulent in mice (44).  
1.2.2.2 A novel two-component system regulates a novel lipid A modification in Vibrio 
cholerae 
Certain lipid A modifications have been shown to be regulated by two-component 
system (TCS) protein networks that act as sentinels for detection and integration of 
various signals in the form of targeted transcriptional regulation. A typical TCS consists 
of a sensor histidine kinase that detects specific environmental queues and a cognate 
response regulator, which carries out changes in expression of a subset of genes known as 
its regulon. Upon recognition of a given signal, the sensor first autophosphorylates and 
then phosphorylates the response regulator, causing it to activate or repress gene 
expression within the regulon. When the signal is no longer present or detectable, the 
sensor deactivates the response regulator by dephosphorylation, thereby terminating 
transcriptional control of affected genes (46–48). Some bacteria like E. coli possess an 
extensive network of well-characterized TCSs, while others may encode only one or two 
known systems.  
The aquatic pathogen Vibrio cholerae has caused millions of infections in 
repeated global pandemics since the early 1800s, producing intense diarrheal disease that 
can quickly lead to death. In a recent major shift for V. cholerae epidemiology, the 
classical biotype responsible for the first six pandemics has been superseded by the El 
Tor biotype, the cause of the current seventh pandemic (49). The El Tor biotype is   
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Figure 1.4: Conditional lipid A modifications in Y. pestis and V. cholerae 
(A) Y. pestis produces endotoxic hexa-acylated lipid A while in the flea host. When it 
enters the human host, it encounters a shift in temperature, which induces synthesis of 
tetra-acylated TLR4-antagonistic lipid A. (B) V. cholerae classical strains produce hexa-
acylated lipid A that is sensitive to CAMPs like polymyxin B. El Tor strains evolved 
machinery to add a glycine or diglycine (pink) to the distal acyl chain, which drastically 
increases CAMP resistance.  
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resistant to the CAMP polymyxin B, while classical strains are not. This phenotypic 
difference has been attributed to the fact that El Tor strains modify their lipid A with 
glycine or diglycine residues, which increase the net positive charge of the outer 
membrane and promote resistance to CAMPs (Fig 1.4B)(50). Addition of this amino acid 
is orchestrated by proteins encoded by the almEFG operon, recently shown to be under 
the transcriptional control of novel TCS, VprAB (50, 51). While the V. cholerae genome 
contains a number of TCSs, VprAB is the first to be identified as playing a role in 
regulation of lipid A structure. Sensor VprB responds to environmental queues present in 
the intestinal lumen including bile and mildly acidic pH, and response regulator VprA 
controls expression of the alm operon upon activation by VprB. Mutants of VprAB do 
not modify their lipid A with glycine, and thus are sensitive to CAMPs. These mutants 
also show colonization defects in a suckling mouse model, establishing VprAB-
dependent glycine modification as important for V. cholerae pathogenesis (52).  
1.2.2.3 Regulation of lipid A modifications by two-component systems in Salmonella 
enterica and Escherichia coli 
Salmonella enterica serovar typhimurium is another enteric pathogen known to 
encode several TCSs that regulate lipid A modification under different growth and life 
cycle conditions. The lipid A produced by this organism is structurally identical to that of 
E. coli when unmodified. Both organisms have evolved complex circuitry at the 
transcriptional and post-translational level to regulate lipid A modifications in different 
environmental conditions. Two major TCSs, PhoPQ and PmrAB, are known to control 
expression of a number of modification enzymes in these enteric organisms; conditions 
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such as low pH and presence of CAMPs can activate both systems, while low levels of 
divalent cations are sensed only by PhoQ and high levels of Fe3+ are sensed only by 
PmrB (40, 53–55). Alterations to the lipid A structure induced by a given external signal 
often change the immunogenicity or charge of the molecule in a manner that helps the 
bacterium survive. For example, S. enterica alters its lipid A structure to better survive in 
the intestinal lumen and within host macrophages, its primary niches during infection (56, 
57). 
The PhoPQ regulon of Salmonella spp. includes two genes involved in lipid A 
modification: pagP, encoding an outer membrane palmitoyl transferase, and pagL, 
encoding an outer membrane deacylase (Fig 1.5)(58, 59). The structural changes that 
these enzymes bring to the lipid A molecule are thought to limit TLR4 stimulation, 
reinforce the barrier function of the outer membrane, and protect against attack by 
CAMPs (60, 61). EptA, a phosphoethanolamine (pEtN) transferase, and ArnT, a 4-
amino-4-deoxy-L-arabinose (L-Ara4N) transferase, are upregulated under PmrB-
activating conditions (62–65). These groups mask the anionic charge of the phosphate 
groups, yielding an outer membrane that is not as attractive to destructive CAMPs (Fig 
1.5)(63, 64).  
While there exists some overlap in which signals are sensed by these two systems, 
they are also linked at a post-translational level by small protein, PmrD (66). pmrD is 
expressed under PhoPQ-activating conditions and as a protein, it maintains PmrA in an 
active transcriptional regulator state (67–69). As a result, CAMP-protective PmrAB-
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dependent lipid A modifications by EptA and ArnT also occur when environmental 
conditions exclusively activate PhoPQ in Salmonella spp. (66). Chapter 3 of this work 
explores the same PhoPQ-PmrAB cross-talk network in E. coli, which was previously 
thought not to be capable of connecting these systems (70).  
 
Figure 1.5: Lipid A modifications in S. enterica and E. coli alter the physiological  
  properties of the molecule 
Salmonella and E. coli modify their lipid A with multiple chemical groups in various 
conditions. Addition of L-Ara4N (green) and pEtN (red) promotes CAMP resistance, 
while removal of the 3-linked acyl chain by PagL and addition of a secondary palmitate 
at the 2-linked primary acyl chain decreases TLR4 stimulation.   
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The following body of research explores two stories in gram-negative organisms 
that occupy vastly different ecological niches, united by the common thread of lipid A 
structure and function. In H. pylori, a Raetz pathway late acyltransferase with the same 
activity as E. coli LpxM but unique substrate preferences is discovered and characterized 
(25). Its activity is essential for downstream modification of H. pylori lipid A and 
survival of this hardy organism. In E. coli, the PmrD protein is found to be an active 
connector of PhoPQ and PmrAB, promoting modification of the lipid A with amine-
containing groups that protect against CAMPs (70). This finding has overturned a 
previous long-held belief in this field that E. coli PmrD is an inactive connector of these 
TCSs.  
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Chapter 2: Identification of a broad family of lipid A late 
acyltransferases with non-canonical substrate specificity1 
2.1 INTRODUCTION 
The outer membrane of most gram-negative bacteria is an asymmetric bilayer, 
with the inner leaflet composed of phospholipids and the outer leaflet consisting of 
lipopolysaccharide (LPS) (1). LPS is anchored to the outer bacterial membrane by the 
lipid A domain. Lipid A, also known as endotoxin, is a bioactive molecule that triggers 
the host innate immune response when it binds the Toll-like receptor 4/myeloid 
differentiation factor 2 (TLR4/MD2) complex (71). High LPS concentrations experienced 
during infection can activate signaling cascades that lead to endotoxic shock, which can 
prove fatal for the host (3, 4). In this way, lipid A is a major virulence factor for most 
gram-negative organisms.  
Interestingly, some organisms produce lipid A that does not elicit a strong 
immune response. For example, Helicobacter pylori lipid A is up to 1000-times less 
immunostimulatory than the typical lipid A of Escherichia coli (33–35). The discrepancy 
in toxicity between E. coli and H. pylori lipid A can be attributed to important structural 
differences in the two biomolecules (Fig 2.1).  E. coli generates a β-(1',6)-linked 
disaccharide of glucosamine that is bis-phosphorylated, hexa-acylated, and attached to 
                                                
1Large portions of this chapter have been previously published (copyright by John Wiley and 
Sons, re-used with permission). Rubin EJ, O’Brien JP, Ivanov PL, Brodbelt JS, Trent MS. 2014. 
Identification of a broad family of lipid A late acyltransferases with non-canonical substrate 
specificity. Mol Microbiol 91:887–899. (E.J.R. designed and performed experiments and wrote 
the manuscript under the supervision of M.S.T.; J.P.O designed and performed the ESI and 
UVPD-MS experiments under the supervision of J.S.B.; P.L.I. assisted in cloning experiments). 
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two Kdo sugars (Fig 2.1A) (71). Conversely, the final H. pylori lipid A structure displays 
alterations in acyl chain length and number, phosphate group and Kdo sugar number, as 
well as addition of a polar functional group, phosphoethanolamine (pEtN) (Fig 2.1B, 
right) (22, 27–29, 72). Importantly, such structural changes have been shown to alter the 
TLR4 response and therefore the innate immune reaction in the host (8, 73). Indeed, H. 
pylori lipid A is a poor stimulator of the TLR4/MD2 complex, which allows it to evade 
the host immune response and establish a long-term infection in the gastric epithelium 
(29, 34, 74, 75).  
As in other gram-negative organisms, H. pylori lipid A is synthesized via the 
Raetz pathway, which builds the lipid A starting from an activated nucleotide sugar donor 
(76). This process occurs in the bacterial cytoplasm and produces a structure very similar 
to that of E. coli lipid A (Fig 2.1B, left). This hexa-acylated species is then heavily 
modified by a 5-enzyme cascade during transport across the inner and outer membranes, 
yielding the final surface-presented structure (Fig 2.1B, right) (22, 27, 29, 72, 77).  
 In E. coli lipid A biosynthesis, the Kdo sugars must be present in order for 2′- and 
3′-secondary acylation of lipid IVA, catalyzed by late acyltransferases LpxL and LpxM, 
respectively (Fig 2.1A) (78). Further, the substrate preferences of the late acyltransferases 
establish their enzymatic order; LpxL acts before LpxM (18, 19).   Here, we characterize 
a lipid A acyltransferase in H. pylori that is functionally similar to but lacks complete or 
significant sequence homology to E. coli LpxM (Table 2.1). This enzyme, from hereon 
referred to as LpxJ, transfers the secondary acyl chain to the 3′-linked primary acyl chain 
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of H. pylori lipid A, similarly to LpxM in E. coli. However, LpxJ can perform 
acyltransfer regardless of the presence of Kdo sugars and can do so before the H. pylori 
LpxL homolog, Jhp0265 (22). The enzymatic flexibility of LpxJ allows for the 
unprecedented option of multiple routes at the end of the lipid A biosynthesis pathway, a 
possibility not observed in E. coli  (Fig 2.9). Ultimately, the altered order of 3′-secondary 
acylation could reflect the importance of this chain in downstream processes, such as 
transport and presentation of H. pylori lipid A. We examine LpxJ homologs in two 
closely related organisms and demonstrate that these enzymes are also capable of non-
ordered 3′-secondary acylation activity. Together, the enzymes studied here represent a 
previously uncharacterized family of lipid A late acyltransferases with homologs in a 
wide range of bacterial species. While functionally related to E. coli LpxM, these proteins 
are different at the primary sequence level, resulting in unique enzymatic characteristics 
and a less stringently ordered lipid A biosynthesis pathway. 
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Figure 2.1 Final steps of the Raetz pathway in E. coli and the missing late 
acyltransferase of H. pylori 
(A) In E. coli once lipid IVA is synthesized, KdtA then transfers 2-Kdo sugars to the 
hydroxyl group at the 6′ position. Only then are secondary acyl chains transferred to the 
2′- and 3′-primary acyl chains by LpxL and LpxM, respectively, generating first penta-
acylated lauroyl-Kdo2-lipid IVA and finally Kdo2-lipid A. Carbon numbers are shown for 
reference in the left-most structure. (B) H. pylori produces a hexa-acylated lipid A 
product via the Raetz pathway (left), which is then modified by a series of enzymes to 
create the structure presented in the outer membrane (right). Previously unknown was the 
identity of the acyltransferase that transfers the secondary acyl chain to the 3′-primary 
acyl chain during Raetz pathway biosynthesis (red question mark). We have identified 
this enzyme as LpxJHp, encoded by gene jhp0255 in H. pylori strain J99.  
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2.2 RESULTS 
2.2.1 H. pylori encodes an enzyme functionally comparable to E. coli LpxM 
 Previously, we characterized H. pylori LpxLHp (jhp0265), a homolog of E. coli 
LpxL that transfers a C18:0 secondary acyl chain to the 2′-linked acyl chain of H. pylori 
lipid IVA (22). Because H. pylori has been shown to produce a hexa-acylated lipid A 
precursor (Fig. 2.1B, left) that is further processed by the modification pathway, it 
follows that an unidentified acyltransferase functionally similar to E. coli LpxM is 
required (30, 72, 79). Stead et al. observed a putative LpxM-like activity by 
demonstrating that purified H. pylori membranes are capable of adding a secondary acyl 
chain to the 3′-linked primary chain of penta-acylated lipid A substrate in vitro (22). 
However, a PSI-BLAST search using LpxM as the query sequence revealed only LpxLHp, 
suggesting that H. pylori encodes a functional equivalent of E. coli LpxM that is not 
identifiable based on sequence homology.  
 We identified jhp0255 as a strong candidate to encode the “missing” late 
acyltransferase by consulting the Pfam database, an online tool that groups proteins by 
predicted functional domains (80). Specifically, we looked within the acyltransferase clan 
(CL0228), which contains proteins with a putative acyl acceptor pocket domain, 
suggesting a functional role in acyl transfer reactions. This clan has four families: a lipid 
A acyltransferase family, of which LpxM and LpxLHp are members, the diacylglycerol 
acyltransferase family, glycerolipid acyltransferase family, and the domain of unknown 
function family (DUF374). The DUF374 protein for H. pylori is Jhp0255, which is 
previously uncharacterized and located close on the chromosome to other previously  
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 studied LPS biosynthesis genes including lpxLHp (81). Because both Jhp0255 and E. coli 
LpxM are grouped into separate families within the same Pfam clan, they likely share a 
distant common ancestor that diverged through evolution. At the primary sequence level, 
however, the H. pylori enzyme differs significantly from LpxM (Table 2.1) and the acyl 
acceptor domain appears to be the only common sequence thread between the two 
proteins. Accordingly, we have reannotated Jhp0255 as LpxJ, as it was discovered in H. 
pylori strain J99.  
 
 
Table 2.1: Genetic relationships between E. coli LpxM and relevant proteins. 
 
aHomology is given as the number of identities, number of positives, number of residues 
(including gaps) in the related segment(s) when compared with E. coli LpxM, a protein of 
323 amino acid residues.  
 
 
 
 
 
 
  
Organism Protein Homology (gaps)a Approximate E values 
Helicobacter pylori LpxJ (Jhp0255) 25, 41, 147 (33) 0.028 
Campyobacter jejuni LpxJ 
(Cjj81176_0482) 
6, 6, 10 (0); 5, 8, 13 (0) 0.63, 1.4 
Wolinella succinogenes LpxJ (Ws1775) 9, 21, 48 (1) 0.37 
Salmonella enterica 
subsp. enterica 
MsbB 300, 314, 323 (0) 0.0 
Klebsiella pneumonia MsbB 270, 291, 323 (0) 0.0 
Haemophilus influenzae MsbB 136, 196, 301 (2) 3e-96 
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Figure 2.2 lpxJHp is an essential gene that can only be knocked-out after prior 
complementation 
PCR analysis of genomic DNA isolated from H. pylori strain J99 wild type (WT), J99 
with an additional copy of lpxJHp inserted into the rdxA locus (rdxA::lpxJHp), and J99 
with a copy of lpxJHp inserted into the rdxA locus and finally the endogenous copy of 
lpxJHp replaced with a kanamycin resistance cassette (rdxA::lpxJHp, lpxJHp::kanR). Lanes 
1-3 show that insertion of lpxJHp into the rdxA locus produces a chromosomal fragment 
~650bp larger than the wild type fragment. Lanes 4-6 show that insertion of the 
kanamycin resistance cassette at the endogenous lpxJHp locus produces a fragment 
~150bp larger. Insertion of the kanamycin cassette at the lpxJHp locus can only occur in a 
strain that already has a second copy of lpxJHp elsewhere on the chromosome (in this 
case, at rdxA). Attempts to chromosomally knock-out lpxJHp without prior 
complementation failed due to the essential nature of the gene. 
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2.2.2 LpxJHp complements a penta-acylated E. coli lpxM mutant, restoring a hexa-
acylated phenotype 
 To investigate the role of LpxJHp in H. pylori lipid A biosynthesis, we attempted 
to generate a mutant strain by replacing its coding sequence in the genome with a 
kanamycin antibiotic resistance cassette. However, multiple efforts to obtain this mutant 
were unsuccessful in several H. pylori strains, suggesting that the gene product is 
essential for viability. Indeed, insertional deletion of lpxJHp was only successful after 
providing the bacterium with a second copy of the gene by chromosomal 
complementation at the rdxA locus (Fig 2.2). Inactivation of the H. pylori rdxA locus 
leads to metronidazole resistance, which can be used to select for colonies containing the 
complemented gene of interest at this locus.  
 In the absence of a viable deletion mutant, we expressed LpxJHp in the E. coli 
lpxM mutant strain BN2 (Table 5.1), which produces a penta-acylated lipid A, to 
determine if LpxJHp could generate hexa-acylated lipid A species in vivo. Indeed, 
chromatographic separation of radiolabeled lipid A isolated from BN2 expressing LpxJHp 
revealed a migration pattern consistent with the presence of hexa-acylated lipid A (Fig 
2.3, lane 3). Hexa-acylated lipid A isolated and analyzed from strain BN1 served as a 
positive control (Table 5.1)(Fig 2.3, lane 1). Strain BN2 containing empty vector 
produced only penta-acylated lipid A (Fig 2.3, lane 2), suggesting that LpxJHp catalyzes 
transfer of the secondary acyl chain to the 3′-linked primary acyl chain of lipid A. These 
findings were confirmed by MALDI-TOF mass spectrometry; LpxJHp transfers a C12:0 
or C14:0 chain (Fig 2.4B), to generate major molecular ions at m/z 1768.3 and 1796.3.  
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Figure 2.3 LpxJHp and homologs in two other Epsilonproteobacteria complement a 
hexa-acylated lipid A phenotype in a penta-acylated E. coli LpxM mutant 
Radiolabeled lipid A from various E. coli strains was isolated and separated by TLC. 
Expression of LpxJHp (lane 3), LpxJCj (lane 4), and LpxJWs (lane 5) in strain BN2, which 
normally produces penta-acylated lipid A (lane 2), complements this penta-acylated 
strain to a hexa-acylated phenotype (as shown for positive control strain BN1, lane 1). 
Asterisks (*) in lanes 3 and 4 correspond to lipid A species formed by alternative 
acylation order (see cartoon at left). The presence of residual penta-acylated product in 
the LpxJCj and LpxJWs strains (dark spots migrating at the same level as BN2 vector 
control, lane 2) suggests these enzymes may not be as efficient as LpxJHp in this system.   
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The lipid A species that results from transfer of a C14:0 chain by LpxJHp is almost 
identical in molecular mass to the lipid A of hexa-acylated control strain BN1 (m/z 
1796.0)(Fig 2.5). Taken together, these results strongly suggest that LpxJHp transfers a 
C12:0 or C14:0 secondary acyl chain to the 3′-linked primary acyl chain of H. pylori lipid 
A.  
2.2.3 Homologs of LpxJHp are found in other Epsilonproteobacteria 
 Due to the unexpected sequence difference between LpxJHp and E. coli LpxM, we 
hypothesized that other bacteria may encode homologs of LpxJ instead of LpxM. In two 
closely related Epsilonproteobacteria, we identified Campylobacter jejuni protein 
Cjj81176_0482 (LpxJCj) and Wolinella succinogenes protein Ws1775 (LpxJWs) as 
homologs of LpxJHp and members of the DUF374 family. The C. jejuni and W. 
succinogenes proteins were expressed individually in strain BN2 and radiolabeled lipid A 
was isolated from each strain. Both proteins complemented the penta-acylated mutant, 
leading to formation of a hexa-acylated lipid A species (Fig 2.3, lanes 4, 5). TLC results 
for C. jejuni and W. succinogenes proteins were confirmed with MALDI-TOF mass 
spectrometry to show that LpxJCj transfers a C16:0 acyl chain and LpxJWs transfers a 
C12:0 chain to the penta-acylated lipid A framework (Fig 2.4C, D).  
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Figure 2.4 MALDI-TOF mass spectrometry of E. coli LpxM mutant, BN2 expressing 
acyltransferase genes from three Epsilonproteobacteria 
  (A) Strain BN2 produces a major molecular ion peak at m/z 1586.0, corresponding to 
penta-acylated lipid A. (B) Expression of LpxJHp in the BN2 background produces two 
main peaks at m/z 1768.3 and m/z 1796.3. The former peak corresponds to addition of a 
C12:0 group and the latter corresponds to addition of a C14:0 group to the 3′-linked acyl 
chain of lipid A. The asterisk (*), which indicates the peak at m/z 1614.0, represents 
penta-acylated lipid IVA with the fifth chain on the 3′-primary acyl chain, which can form 
before 2′ secondary acylation occurs. This species is the same as the (*)-designated 
species in Fig. 2, lane 3. (C) Expression of LpxJCj in the BN2 background produces a 
major peak at m/z 1824.3, corresponding to C16:0 addition to the lipid A. The peak at m/z 
1586.0 represents residual penta-acylated lipid A. The asterisk (*), which indicates the 
peak at m/z 1642.1, represents penta-acylated lipid IVA with the fifth chain on the 3′-
primary acyl chain, which can form before 2′ secondary acylation occurs. This species is 
the same as the (*)-designated species in Fig. 2, lane 4. (D) Expression of LpxJWs in the 
BN2 background produces hexa-acylated lipid A with a peak at 1768.0, corresponding to 
C12:0 addition to the lipid A.   
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Figure 2.5 MALDI-TOF mass spectrometry of hexa-acylated control strain BN1 
BN1 (Table 5.1) produces a hexa-acylated lipid A with major peak at m/z 1796.0. This 
strain also produces a residual penta-acylated species, represented by the peak at m/z 
1585.8. 
 
2.2.4 DUF374 proteins are found in a diverse range of organisms 
 Further investigation into Pfam family DUF374 revealed that over 500 species 
encode at least one protein that can be classified into this predicted acyltransferase 
family. LpxJHp has putative homologs in a surprisingly large number of organisms 
ranging from other bacterial classes including Alpha, Delta, and Zetaproteobacteria, to 
other phyla including Fusobacteria, Chlamydiae, Acidobacteria, and Spirochaetes (Table 
2.2). Relevant BLAST scores demonstrating homology between LpxJHp and a number of 
other DUF374 proteins are provided in Table 2.3. Of note, the organisms that encode a 
homolog of LpxJHp possess a homolog to E. coli LpxL, but not LpxM (Table 2.2). 
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Table 2.2: LpxJ homologs in Pfam DUF374 
 
  
Organism Strain Class 
E. coli LpxL 
homolog 
E. coli LpxM 
homolog LpxJ homolog 
Helicobacter 
pylori 
J99 Epsilonproteobacteria Yes/Jhp0265 No/-- Yes/LpxJHp 
Helicobacter 
hepaticus 
ATCC 
51449 
Epsilonproteobacteria Yes/HH0982 No/-- Yes/HH1275 
Campylobacter 
jejuni 
81-176 Epsilonproteobacteria Yes/Cjj81176_1151 No/-- Yes/LpxJCj 
Campylobacter 
fetus subsp. fetus 
82-40 Epsilonproteobacteria Yes/CFF8240_1400 No/-- Yes/CFF8240_1376 
Wolinella 
succinogenes 
DSM174
0 
Epsilonproteobacteria Yes/Ws1908 No/-- Yes/LpxJWs 
Bartonella 
bacilliformis 
KC583 Alphaproteobacteria Yes/BARBAKC583
_0617 
No/-- Yes/BARBAKC583
_1205 
Brucella 
melitensis 
ATCC 
23457 
Alphaproteobacteria Yes/BMEA_A0889 No/-- Yes/BMEA_A0457 
Rickettsia 
rickettsia 
Hlp #2 Alphaproteobacteria Yes/RPK06045 No/-- Yes/RPK00655 
Desulfovibrio 
vulgaris 
Miyazaki 
F 
Deltaproteobacteria Yes/DvMF_0365 No/-- Yes/DvMF_0366 
Fusobacterium 
nucleatum 
CC53 Fusobacteriales Yes/H848_01687 No/-- Yes/H848_04757 
Escherichia  
coli 
MG1655 Gammaproteobacteria Yes/LpxL Yes/LpxM No/-- 
Salmonella 
enterica serovar 
Typhimurium 
LT2 Gammaproteobacteria Yes/LpxL Yes/LpxM No/-- 
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Although enzymatic activity has not been confirmed for all members of DUF374, our 
results strongly suggest that this previously unstudied protein family contains 
acyltransferases that participate in lipid A biosynthesis in place of LpxM. 
Table 2.3: Homologs of LpxJHp found in DUF374 
 
aAlignments scores (I, identities; P, positives; G, gaps) and E values for each protein 
compared with H. pylori Jhp0255 using NCBI BLASTP2.2.27. 
 
2.2.5 LpxJHp acts on tetra- or penta-acylated lipid A, with or without Kdo sugars 
 In E. coli, LpxL and LpxM can only acylate the lipid A structure after the two 6′-
Kdo sugar residues are added to the tetra-acylated lipid IVA donor (Fig 2.1A)(19). The 
same is true for LpxLHp, which also requires Kdo addition for activity (22). Surprisingly, 
enzymatic assays using radiolabeled lipid IVA substrate showed that LpxJHp does not   
Organism Protein I,P,G (%)a E valuea 
Helicobacter pylori 
 
Jhp0255 (LpxJHp) 100, 100, 0 0.0 
 
Helicobacter hepaticus 
 
HH1275 41, 61, 1 4e-55 
Campylobacter jejuni 
 
Cjj81176_0482 (LpxJCj) 33, 52, 1 6e-41 
Campylobacter fetus subsp. fetus 
 
CFF8240_1376 41, 60, 1 3e-35 
Wolinella succinogenes 
 
Ws1775 (LpxJWs) 44, 66, 1 9e-52 
Bartonella bacilliformis 
 
BARBAKC583_1205 31, 42, 7 3e-10 
Brucella melitensis 
 
BMEA_A0457 26, 44, 7 1e-08 
Rickettsia rickettsia 
 
RPK00655 26, 46, 7 4e-17 
Desulfovibrio desulfuricans 
 
DvMF_0366 32, 48, 10 2e-25 
Fusobacterium nucleatum H848_04757 34, 54, 1 3e-23 
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require the presence of Kdo sugars to acylate lipid A (Fig 2.6A). This is particularly 
interesting given the fact that it is expected to catalyze the final step in the pathway as 
LpxM does in E. coli. Beyond this, the enzyme also displays flexibility in terms of 
substrate acyl chain number, adding to both Kdo2-lipid IVA (tetra) and lauroyl-Kdo2-lipid  
IVA (penta) (Fig 2.6A).  
Figure 2.6 Enzymatic characteristics of LpxJHp 
(A) Membranes from strain BN2 containing empty vector or pWSK29jhp0255 (lpxJHp) 
were assayed with various [4′-32P]-labeled lipid substrates and 5µM C12:0 acyl-ACP. 
Membranes from the empty vector strain showed no activity from endogenous E. coli 
proteins, while membranes expressing LpxJHp acylated all substrates except Kdo2-[4′-32P] 
lipid A. Acylated reaction products are indicated with red asterisks (*). (B) BN2 
membranes expressing LpxJHp were tested with Kdo2-[4′-32P] lipid IVA and 5µM acyl-
ACPs/acyl-CoAs as labeled. LpxJHp uses C12:0 and C14:0 acyl-ACPs as donor 
molecules. Acylated reaction products are indicated with red asterisks (*). 
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The ability of LpxJHp to add to both a tetra- and penta-acylated substrate suggests that its 
activity can precede LpxLHp activity, such that secondary acylation at the 3′-primary 
chain precedes secondary acylation at the 2′-primary chain. This order is reverse of the 
strict LpxL-then-LpxM order found in E. coli and many other Gram-negative organisms 
(18, 19).  
 LpxJHp does not, however, transfer an acyl chain to hexa-acylated substrate Kdo2-
lipid A, which already has secondary acyl chains attached to the 2′- and 3′-primary chains 
(Fig 2.6A). With this substrate, any further acylation by LpxJHp would have to occur at 
the hydroxyl groups of the primary acyl chains attached to the proximal glucosamine of 
the lipid A molecule. These results demonstrate that LpxJHp only transfers an acyl chain 
to the distal glucosamine (2′- or 3′-primary chain) and not the proximal (2- or 3-primary 
chain) side of the lipid A molecule. To confirm this result, we expressed LpxJHp in a tetra-
acylated E. coli strain (MKV15b, Table 5.1) to allow the enzyme access to all possible 
secondary acylation positions, then subjected isolated lipid A to ultraviolet photo-
dissociation (UVPD) mass spectrometry. UVPD of isolated lipid A allowed identification 
of a fragment ion (m/z 738.4, cleavage 12) that represents the unmodified proximal 
glucosamine of lipid A, which does not change between vector control and the strain 
expressing LpxJHp (Fig 2.8A,B).  This confirms that the acylation pattern of the proximal 
sugar does not change upon expression of the Helicobacter acyltransferase, and therefore 
acylation by this enzyme must occur on the distal glucosamine.  
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 With regard to acyl chain donor, LpxJHp is analogous to E. coli LpxM in that it 
can only utilize acyl-ACPs rather than acyl coenzyme A (acyl-CoA), preferring C12:0-
ACP and C14:0-ACP (Fig 2.6B)(19). Importantly, isolated H. pylori lipid A has either a 
C12:0 or C14:0 secondary acyl chain at the 3′-primary acyl chain (29), suggesting that 
our in vitro system closely mimics an in vivo environment for this acyltransferase. These 
results combined with the ability of this enzyme to promote formation of hexa-acylated  
lipid A in a penta-acylated mutant allow us to definitively conclude that it adds a 
secondary acyl chain to the 3′-linked primary acyl chain of the lipid A molecule.  
2.2.6 Campylobacter and Wolinella LpxJ only use tetra-acylated lipid A as substrate 
 Enzymatic activities of LpxJCj and LpxJWs were assayed with the same in vitro 
system and radiolabeled lipid substrates used for LpxJHp. Both enzymes were unable to 
acylate a penta-acylated lipid A substrate and could only act on a tetra-acylated lipid A 
substrate, independent of Kdosylation state (Fig 2.7A). These results were initially 
confounding, given that both enzymes were capable of rescuing a penta-acylated mutant 
to a hexa-acylated phenotype in vivo. Taken together, this evidence indicates that LpxJCj 
and LpxJWs can only function before their respective 2′-secondary acyltransferase LpxL 
enzymes, requiring exclusively tetra-acylated substrate for activity (Fig 2.9). Similarly to 
LpxJHp, neither LpxJCj nor LpxJWs utilized hexa-acylated Kdo2-lipid A (Fig 2.7A). These 
results were also confirmed by UVPD mass spectrometry of lipid A isolated from strains 
individually expressing LpxJCj and LpxJWs. The fragment ion representing the unmodified 
proximal side of the lipid A molecule was observed in lipid A from both strains   
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Figure 2.7 Enzymatic characteristics of LpxJCj and LpxJWs 
(A) Membranes from strain BN2 containing pWSK29cjj81176_0482 (lpxJCj) or 
pWSK29ws1775 (lpxJWs) were assayed with various [4′-32P]-labeled lipid substrates and 
5µM C12:0 acyl-ACP. LpxJCj and LpxJWs acylate [4′-32P] lipid IVA and Kdo2-[4′-32P] 
lipid IVA substrates. Acylated reaction products are indicated with red asterisks (*). 
Empty vector control is the same as shown in Figure 4A. LpxJCj membranes (B) and 
LpxJWs membranes (C) were assayed with Kdo2-[4′-32P] lipid IVA and 5µM acyl-ACPs/ 
acyl-CoAs as labeled. LpxJCj uses C16:0 and C18:0 acyl-ACPs as donor molecules, and 
LpxJWs uses C12:0 acyl-ACP. Acylated reaction products are indicated with red asterisks 
(*). 
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(m/z 738.4, cleavage 12), which demonstrates that acyl chain addition by each enzyme 
occurs at the distal glucosamine (Fig 2.8A,C,D). 
In agreement with LpxJHp, both LpxJCj and LpxJWs use acyl-ACP as a donor 
molecule, but not acyl-CoA, where LpxJCj can use C16:0 and C18:0 acyl-ACPs and 
LpxJWs prefers C12:0 acyl-ACP (Fig 2.7B, C). Although the Campylobacter enzyme can 
transfer C18:0, this is not likely to represent what occurs in vivo, as C. jejuni does not 
typically incorporate C18:0 into its lipid A structure. This activity may reflect relaxed 
substrate specificity or result from the available acyl-ACP substrate pool within the 
bacterial cell (82). 
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Figure 2.8 UVPD mass spectra of doubly deprotonated lipid A species and 
corresponding fragmentation maps  
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(A) Empty vector (Mr = 1404.85 Da), (B) H. pylori LpxJ (Mr = 1615.05 Da),  (C) C. 
jejuni LpxJ (Mr = 1643.08 Da), and (D) W. succinogenes LpxJ (Mr = 1587.02 Da). 
Precursor fragment ions are labeled with an asterisk. Key fragment ions that allow the 
location of the extra acyl chain to be determined are labeled in red font. Cleavage sites 
that lead to isobaric fragment ions are italicized.  
 
2.2.7 LpxJ activity can precede LpxL activity 
 In vitro assay results for the three LpxJ enzymes demonstrate their ability, or 
necessity, to perform acyltransfer to the 3′-primary chain before their respective LpxL 
enzymes transfer to the 2′-primary chain. This altered acylation order is unprecedented 
and in stark contrast to the strict LpxL-then-LpxM order established in E. coli. Evidence 
for reversed secondary acylation order can also be found in the radiolabeled lipid A 
isolated from strain BN2 expressing LpxJHp and LpxJCj. The asterisks (*) in Fig 2.3, lanes 
3 and 4, mark penta-acylated lipid A species that likely have the fifth chain attached as a 
secondary acyl chain to the 3′- as opposed to the 2′-primary chain. For example, LpxJCj 
transfers a C16:0 chain to the 3′-primary acyl chain, which generates a more hydrophobic 
product (*, lane 4) than penta-acylated BN2 lipid A, which has a secondary C12:0 chain 
at the 2′-primary chain (lower spot). The same is true for LpxJHp, which transfers a C14:0 
chain yielding a product (*, lane 3) that is slightly more hydrophobic than penta-acylated 
BN2 lipid A. Importantly, LpxJHp is more efficient in this in vivo system than the other 
two enzymes, probably due to its more flexible substrate specificity specificity. Both the 
alternative penta-acylated species produced by LpxJHp and LpxJCj are visible in their   
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MALDI-TOF spectra, annotated with an asterisk (*) in Fig 2.4B and C, respectively. 
Because LpxJWs transfers a C12:0 chain, its unique 3′-penta-acylated structure cannot be 
discerned from the E. coli structure (Fig 2.3, lane 5; Fig 2.4D).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 Multiple routes are possible at the end of the Raetz pathway in H. pylori and 
C. jejuni 
(A) Due to the relaxed substrate specificity of LpxJHp, H. pylori lipid A biosynthesis 
could follow three routes to the hexa-acylated end-product. (B) LpxJCj is specific for a 
tetra-acylated substrate regardless of Kdo sugars. Therefore, it could follow two routes to 
the hexa-acylated lipid A biosynthesis end-product. The same is true in W. succinogenes 
lipid A biosynthesis. This model does not consider the substrate specificities of KdtA and 
LpxL in these organisms, which are not fully characterized and will likely also determine 
the precise pathway taken.    
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2.3 DISCUSSION 
 Most gram-negative organisms produce lipid A, a complex bioactive molecule 
that anchors lipopolysaccharide to the outer bacterial membrane and is required for 
bacterial viability (76). Although the lipid A biosynthesis pathway is generally well-
conserved across gram-negative bacteria, there remain exceptions. Here, we identify and 
characterize a previously unknown lipid A acyltransferase in H. pylori and two homologs 
in closely related Epsilonproteobacteria. These enzymes are distant by sequence from E. 
coli LpxM but perform a similar function, transferring a secondary acyl chain to the 
existing 3′ hydroxyacyl chain of lipid A (Fig 2.1, 2.9). 
 Although LpxJ and E. coli LpxM both transfer an acyl chain to the same position 
during lipid A biosynthesis in their respective organisms, they are unexpectedly different 
at the primary sequence level (Table 2.1) and possess distinct enzymatic characteristics. 
The only feature that LpxJ shares with LpxM is the presence of a putative acyl-acceptor 
binding pocket requisite for acyltransferase activity. Even within this binding pocket, 
however, there are divergences between LpxJ and LpxM. Specifically, LpxM contains 
the conserved H(X)4D/E active site motif, which was first identified in the glycerol-3-
phosphate acyltransferase protein and is found in glycerophospholipid acyltransferases 
across bacterial, plant, and animal kingdoms (83–86). Within this active site motif the 
histidine and aspartic acid, or glutamic acid, residues act as an invariant catalytic dyad 
that activates the acceptor hydroxyl on the 3′-primary acyl chain of lipid A for 
nucleophilic attack of the acyl-ACP thioester bond (86). LpxJ and homologs in the 
DUF374 family lack the proximal coordinating aspartic or glutamic acid residue, which 
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suggests that the active site in DUF374-containing proteins has a different structural 
organization or acts through a different coordinating residue (83). Ultimately, this altered 
active site organization could change enzymatic substrate specificity, as the H(X)4D/E 
motif found in LpxL and LpxM is known to contact and coordinate the substrate during 
catalysis. 
 E. coli LpxM strongly prefers penta-acylated lipid A substrates and only shows 
activity on a tetra-acylated substrate when artificially over-expressed (19). This 
preference determines its activity as the last enzyme of the E. coli Raetz pathway, 
generating the LpxL-then-LpxM acylation order. Conversely, a novel feature of LpxJHp is 
its ability to act on both penta- and tetra-acylated substrates (Fig 2.6A). This suggests that 
it is capable of adding a secondary chain to the 3′-primary acyl chain before LpxLHp adds 
a secondary chain to the 2′-primary acyl chain. Therefore, this enzyme does not require 
presence of a secondary acyl chain at the 2′-primary chain for enzymatic activity. 
Interestingly, LpxJCj and LpxJWs add only to a tetra-acylated lipid A, implying that these 
proteins strictly act in the reverse order of the canonical E. coli pathway, specifically 
requiring the absence of a secondary acyl chain on the 2′-primary chain for activity (Fig 
2.7A, 2.9). In the case of LpxJHp, the observed enzymatic flexibility could be the result of 
altered substrate specificity relative to the C. jejuni, W. succinogenes, and E. coli 
proteins, each of which utilizes a very specific (albeit different) lipid substrate. Further, 
LpxJHp, LpxJCj, and LpxJWs are able to perform acyltransfer regardless of the presence of 
Kdo sugars (Fig 2.6A, 2.7A); this introduces another deviation from the E. coli pathway, 
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which requires Kdosylated lipid A before LpxL and LpxM can add the secondary acyl 
chains (18, 19). With this, the enzymatic characteristics of LpxJ introduce the possibility 
of several routes in the final steps of the Raetz pathway, specifically, altered acylation 
and Kdosylation order (Fig 2.9). Some uncertainties remain as to how the observed in 
vitro enzymatic characteristics of these acyltransferases compare to precise activities in 
vivo. For example, LpxLHp has not yet been shown to use LpxJHp-acylated Kdo2-lipid IVA 
(that is, Kdo2-lipid IVA with a secondary acyl chain on the 3′-primary acyl chain) as 
substrate, only Kdo2-lipid IVA. This is in part due to the biochemical difficulty associated 
with generating the 3′-penta-acylated in vitro substrate. Without this result, it is difficult 
to definitively conclude that LpxLHp participates in reversed acylation order during in 
vivo lipid A biosynthesis. Interestingly, the C. jejuni LpxJ protein can work in concert 
with E. coli LpxL to produce hexa-acylated lipid A, despite the fact that both enzymes 
prefer a tetra-acylated susbtrate (Fig 2.3, lane 4). This result suggests a possible trade-off 
in substrate specificity in vivo, allowing both LpxJCj and LpxL to sometimes use a less 
preferred penta-acylated substrate in order to complete lipid A biosynthesis in the in vivo 
E. coli system. However, this described activity for LpxJCj would be best understood in 
the organism of origin, C. jejuni.   
 The evolutionary pressure selecting for various orders of secondary acylation is 
unclear, but may be determined by the specificity of lipid transport protein, MsbA. This 
flippase translocates lipid A across the inner membrane from the cytoplasmic to 
periplasmic lipid leaflet after completion of the Raetz pathway; translocation by MsbA is 
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required for ultimate presentation of lipid A molecules on the bacterial surface (73). We 
hypothesize that the essential nature of LpxJ could be tied to MsbA, which might only 
recognize hexa-acylated lipid A or penta-acylated lipid A with a secondary acyl chain 
present at the 3′- primary acyl chain. If this were true, MsbA would not be able to flip the 
lipid A to the periplasmic leaflet in an LpxJ mutant, thus halting transport of the molecule 
to the bacterial cell surface leading to cell death. This theory is corroborated by the fact 
that mutants in LpxLHp are viable (22), suggesting that the precise location of the 
secondary acyl chain at the 3′- and not the 2′-primary chain is critical for recognition of 
the lipid substrate by MsbA in H. pylori. The reversal in late acylation order could be a 
response to this potential narrow substrate range of MsbA as an effort to ensure that the 
3′-primary chain gets acylated first since survival depends on it. In C. jejuni and W. 
succinogenes, there may be stronger pressure to maintain the reversed late acylation 
order, as their respective LpxJ enzymes can act only before LpxL, while LpxJ activity in 
H. pylori can precede or follow LpxL. It is currently unclear why these organisms 
function only in the reverse order while the H. pylori enzyme is more flexible. 
  The three enzymes characterized in this paper are all found in 
Epsilonproteobacterial species. However, the DUF374 protein class by which they are 
functionally classified represents an expansive array of other organisms including classes 
of bacteria such as Alpha, Delta, and Zetaproteobacteria; and even other phyla such as 
Fusobacteria, Chlamydiae, Acidobacteria, and Spirochaetes. The presence of DUF374 
proteins in LpxM-deficient bacteria combined with the biochemical data presented here 
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strongly suggest that LpxJ represents a hitherto uncharacterized group of lipid A 
secondary acyltransferases.  
 The three DUF374 enzymes studied in this work possess novel characteristics 
relative to E. coli LpxM in terms of substrate specificity and order of acylation, 
suggesting that differences at the primary sequence level can explain differences in 
function. Additional work is required to determine a molecular explanation for the 
divergence in biochemical activity based on differences in residues within the predicted 
acyltransfer active site and is ongoing in our laboratory. Study of these enzymes is 
particularly important because modification and ultimate surface presentation of H. pylori 
lipid A is dependent on formation of a Raetz pathway end-product that can be recognized 
by the MsbA transport machinery. The unusual order of H. pylori lipid A biosynthesis 
demonstrates that one enzyme and its biochemical characteristics can alter the trajectory 
of a well-conserved biochemical pathway that is essential for bacterial survival.   
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Chapter 3: PmrD is required for modifications to Escherichia coli 
endotoxin that promote antimicrobial resistance2 
3.1 INTRODUCTION 
Bacteria often encounter adverse conditions that threaten survival in an 
unpredictable environment. The first line of defense for most gram-negative bacteria is 
the outer membrane, which contains lipopolysaccharide (LPS) in the outer leaflet that 
interfaces with the surroundings (1). LPS is a multi-component macromolecule anchored 
to the bacterial membrane via its lipid A domain, a potent activator of the host innate 
immune response (2, 48).  In the presence of environmental stressors, numerous gram-
negatives have evolved machinery to modify the lipid A moiety with chemical groups 
that promote bacterial survival by creating a fortified, more resistant outer membrane 
(73).  
Lipid A modifications are often regulated by complex two-component system 
(TCS) protein networks that coordinate detection of various signals with targeted 
transcriptional regulation. A typical TCS consists of a sensor histidine kinase that detects 
specific environmental signals and a cognate response regulator, which carries out 
changes in expression of a subset of genes known as its regulon. Upon recognition of a 
given signal, the sensor first autophosphorylates and then phosphorylates the response 
regulator, causing it to activate or repress gene expression within the regulon. When the 
                                                
2 Large portions of this chapter have been previously published. Rubin EJ, Herrera CM, Crofts 
AA, Trent MS. 2015. PmrD Is Required for Modifications to Escherichia coli Endotoxin That 
Promote Antimicrobial Resistance. Antimicrob Agents Chemother 59:2051–2061. (E.J.R. 
designed and performed experiments and wrote the manuscript under the supervision of M.S.T.; 
C.M.H. performed quantitative PCR experiments; A.A.C. analyzed RNA sequencing data). 
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signal is no longer present or detectable, the sensor deactivates the response regulator by 
dephosphorylation, thereby terminating transcriptional control of affected genes (46–48). 
The research herein involves two such systems: PhoP-PhoQ (PhoPQ) and PmrA-PmrB 
(PmrAB), where the former protein in each pair is the response regulator and the latter is 
the sensor histidine kinase. PhoQ responds to queues including depletion of Mg2+ and the 
presence of cationic antimicrobial peptides (CAMPs) (40, 55, 87). Although its in vivo 
relevance is still to be fully elucidated, micromolar Mg2+ is a strong activating signal for 
PhoQ commonly used in the laboratory. PmrB senses CAMPs, mildly acidic pH, and 
high Fe3+ concentrations (54, 88, 89). These two major TCSs are widely distributed 
across gram-negative bacteria, particularly in enteric genera including Salmonella, 
Escherichia, Klebsiella, Shigella, and Citrobacter. Activation of PhoPQ and/or PmrAB 
affects numerous cellular processes, among them, in certain organisms, the induction of 
various lipid A modifications (Fig 3.1A).  
For instance, the PmrAB regulon includes two genes involved in lipid A 
modification: eptA, coding for a phosphoethanolamine (pEtN) transferase, and arnT, 
coding for a 4-amino-4-deoxy-L-arabinose (L-Ara4N) transferase (62–65). Enzymes 
EptA and ArnT function at the inner membrane, transferring their respective amine-
containing residues to the lipid A phosphate groups before transport across the periplasm 
(Fig 3.1B)(63, 65). Decoration of lipid A with pEtN or L-Ara4N groups masks the charge 
of one or both of its anionic phosphates. This reduces the net-negative charge of the 
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molecule, and the outer membrane as a whole, which helps protect the bacterium from 
positively-charged CAMPs (Fig 3.1B)(63, 64).  
 In S. enterica, PmrAB-dependent genes can also be activated indirectly in a 
process that requires cross talk through PhoPQ (66). The vehicle for interaction between 
these two-component systems is PmrD, a small PhoP-activated protein that binds to and 
mechanically blocks dephosphorylation of activated phospho-PmrA by its cognate 
sensor, PmrB (67–69)(Fig 3.1B). In effect, PmrD helps maintain PmrA in its active state, 
allowing it to continue influencing transcription of genes in its regulon. Consequently, 
eptA and arnT are also transcribed when environmental conditions exclusively activate 
PhoPQ, such as in low Mg2+. In this way, disparate environmental signals that activate 
PhoPQ or PmrAB ultimately lead to the same phenotypic outcome in S. enterica: lipid A 
modifications that protect against CAMPs (66).  
Conversely, cross talk between PhoPQ and PmrAB is thought not to occur in E. 
coli. Winfield and Groisman previously demonstrated that when wild-type K-12 strain 
MG1655 is grown in low Mg2+, PmrA-dependent genes are not activated and bacterial 
survival is extremely impaired upon exposure to CAMP polymyxin B (90). These cellular 
responses instead require direct activation of PmrAB, suggesting that in E. coli, this 
system is not connected with PhoPQ. This phenotypic difference was first attributed to 
functional divergence between the Salmonella and E. coli PmrD proteins, suggesting that 
PmrD is an inactive connector of PhoPQ and PmrAB in the latter organism (90). 
However, it was later found that E. coli PmrD promotes connection of PhoPQ and 
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PmrAB when expressed heterologously in S. enterica (91). Ultimately, E. coli PmrB was 
demonstrated to possess vigorous phosphatase activity that exceeds that of its S. enterica 
homolog. Together, these findings suggested that in E. coli, PhoPQ and PmrAB are 
disconnected not because PmrD is inactive but because PmrB dephosphorylates PmrA 
faster than PmrD can protect it (91).  
 Former studies have analyzed gene expression and CAMP survival data to define 
a role for PmrD in E. coli, but have not involved phenotypic analysis of the lipid A. The 
lipid A profile can reveal the presence or absence of common structural modifications, 
including pEtN and L-Ara4N, and is therefore a direct read-out for activation of 
modification machinery and CAMP resistance. The structure of this molecule determines 
the biochemical status of the outer membrane and should agree with gene expression and 
survival data. Here, we isolate lipid A from wild-type and pmrD mutant E. coli to 
discover unexpectedly that, 1) pEtN/L-Ara4N modifications are present on lipid A 
isolated from wild-type E. coli grown in micromolar Mg2+, and 2) under the same low 
Mg2+ conditions, pmrD is required for and actively promotes these PmrA-dependent 
modifications. In line with this, we proceed to confirm that pmrD is important for 
bacterial survival upon exposure to polymyxin B and influences expression of PmrA-
dependent genes as shown by RNAseq analysis. Intriguingly, our findings also uncover 
the existence of a second PhoPQ-independent system that activates PmrD and therefore 
addition of PmrA-dependent pEtN and L-Ara4N groups to the lipid A in low Mg2+ 
growth conditions. In all, this research establishes that communication does occur 
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between PhoPQ and PmrAB in E. coli through PmrD, but in a more complex manner 
than expected.  
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Figure 3.1 E. coli and S. enterica modify lipid A in response to environmental signals, 
altering the integrity of the outer membrane 
(A) (Left) Typically, E. coli produces a lipid A structure comprised of a β-(1',6)-linked 
disaccharide of glucosamine that is bis-phosphorylated and hexa-acylated (2). Select 
glucosamine carbons are numbered in red. (Right) Lipid A can be modified by numerous 
enzymes and under various conditions. Modifications include addition of L-Ara4N by 
ArnT (green) and pEtN by EptA (red), addition of a phosphate group at the 1-phosphate 
by LpxT (brown), removal of the 3'-linked acyl chains by LpxR (purple), hydroxylation 
of the 3'-secondary acyl chain by LpxO (gray), removal of the 3-linked acyl chain by 
PagL (pink), and addition of a secondary palmitate chain at the 2-linked primary acyl 
chain by PagP (blue). Asterisks designate enzymes found in S. enterica, but not E. coli K-
12. pEtN and L-Ara4N positions may be reversed and/or double addition of residues may 
occur (57, 92). (B) Model for PmrD-mediated crosstalk between PhoPQ and PmrAB. 
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Inner membrane sensor PhoQ is activated by low Mg2+ or CAMPs in the periplasm (40). 
It autophosphorylates then activates the cytosolic response regulator, PhoP, which 
increases transcription of the pmrD gene. The PmrD protein binds to phospho-PmrA, a 
response regulator associated with sensor PmrB. PmrD mechanically inhibits 
desphosphorylation of PmrA by PmrB, allowing continued transcription of PmrA-
dependent genes including eptA and arnT. Ultimately, PmrD promotes addition of pEtN 
and L-Ara4N to the lipid A in PhoPQ-activating conditions, leading to polymyxin 
resistance. Our results implicate a second system (question mark) that is able to activate 
PmrD in an E. coli phoPQ double mutant. 
3.2 RESULTS 
3.2.1 pEtN and L-Ara4N lipid A modifications are induced in wild-type E. coli 
grown in low Mg2+ and are pmrD-dependent 
 Our laboratory has routinely demonstrated that E. coli grown in either rich media 
(such as luria broth) or minimal media containing high concentrations of Mg2+ (1-10 mM) 
produces 1-diphosphate lipid A. The 1-diphosphate structural variant arises when the 
inner membrane kinase LpxT (Fig 3.1A) transfers a phosphate group from undecaprenyl 
pyrophosphate to the 1-phosphate group of lipid A (89, 93). Conversely, when E. coli is 
cultured in low concentrations of Mg2+ (10-100 µM), we see lipid A containing PmrA-
dependent lipid A modifications (pEtN and L-Ara4N) present in the radiolabeled profile 
(89). Here, we sought to repeat this result, and build on it to investigate a potential role 
for pmrD in the modification of E. coli lipid A. To this end, 32P-radiolabeled lipid A was 
isolated from wild-type, pmrD-, and complemented pmrD- E. coli strains in the W3110 
K-12 background grown in both high (10 mM) and low (10 µM) Mg2+ N-minimal 
medium (Fig 3.2A). As previously observed, wild-type E. coli grown in low Mg2+ 
integrated both pEtN and L-Ara4N modifications in single and various double 
combinations (Fig 3.2A, lane 4), when compared with WD101, a strain constitutively   
 
 
53 
 
Figure 3.2 pmrD is required for addition of pEtN and L-Ara4N to lipid A in low Mg2+ 
conditions 
Lipid A species observed in the profiles are depicted as cartoons; L-Ara4N, green 
hexagon and pEtN, red circle. Positive control strain WD101 produces lipid A 
constitutively modified with pEtN and L-Ara4N. (A) E. coli W3110 strains were grown 
in N-minimal medium with either 10 mM Mg2+ (high, lanes 1-3) or 10 µM Mg2+ (low, 
lanes 4-6). W3110 pmrD was expressed from low-copy plasmid pWSK29 in the W3110 
pmrD mutant. (B) E. coli MG1655 strains were grown in N-minimal medium with 10 µM 
Mg2+. MG1655 pmrD was expressed from low-copy plasmid pWSK29 in the MG1655 
pmrD mutant. (C) W3110 pmrD from EHEC or ETEC was expressed from low-copy 
plasmid pWSK29 in the W3110 pmrD mutant in N-minimal medium with 10 µM Mg2+. 
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expressing pmrA (63). Lipid A species modified at both phosphates may have either 
double pEtN, double L-Ara4N, or one of each group (57, 63, 65). In notable opposition to 
the wild-type lipid A profile, these modifications were completely absent in the pmrD 
mutant grown in the same conditions (Fig 3.2A, lane 5), while complementation of the 
pmrD mutant restored the presence of pEtN/L-Ara4N modifications (Fig 3.2A, lane 6). 
Conversely, lipid A profiles of both wild-type and pmrD- strains grown in high Mg2+ 
revealed a 1-diphosphate phenotype (Fig 3.2A, lanes 1, 2). pEtN/L-Ara4N modifications 
are absent in this growth condition presumably because high Mg2+ suppresses PhoPQ and 
thus pmrD transcription (40). However, when pmrD is expressed in trans in a pmrD 
mutant strain grown in high Mg2+, pEtN/L-Ara4N modified lipid A is observed instead of 
the 1-diphosphate variant (Fig 3.2A, lane 3). This demonstrates that exogenous 
expression of pmrD from a low-copy plasmid is sufficient to induce PmrA-dependent 
lipid A modifications in a growth condition where they are otherwise not observed. 
 We also investigated the lipid A profile of closely related K-12 E. coli strain 
MG1655 to determine if our observations were strain specific. MG1655 was chosen 
based on its use in previous studies that questioned functionality of PmrD and the link 
between PhoPQ and PmrAB in E. coli (90). Our results establish that pEtN and L-Ara4N 
groups are also added to the lipid A when this K-12 strain is grown in low Mg2+ and that 
pmrD is required for their presence (Fig 3.2B). Further, expression of pmrD from both 
enterohemorrhagic E. coli (EHEC) and enterotoxigenic E. coli (ETEC) in the W3110  
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Figure 3.3 MALDI-TOF mass spectrometry of lipid A from E. coli W3110 wild-type, 
pmrD-, and complemented pmrD mutant in high and low Mg2+ 
Structures and corresponding exact masses are provided for reference. (A-C) Lipid A 
from W3110 wild-type, pmrD-, and complemented pmrD- strains grown in 10 mM Mg2+ 
(high) generate major molecular ion peaks at m/z 1796.4, 1796.1, and 1797.3, 
respectively. These peaks correspond to hexa-acylated, bis-phosphorylated lipid A. The 
complemented pmrD mutant also produces minor peaks corresponding to single addition 
of pEtN (m/z 1920.3) and L-Ara4N (m/z 1927.3). (D) Lipid A from W3110 wild-type 
grown in 10 µM Mg2+ (low) produces a molecular ion at m/z 1797.0, representing a hexa-
acylated, bis-phosphorylated species. It also generates major peaks corresponding to lipid 
A singly modified with pEtN (m/z 1919.9) and L-Ara4N (m/z 1927.1), as well as double 
modification with one of each residue at each phosphate (m/z 2050.0). The peak at m/z   
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1848.1 corresponds to 1-dephosphorylated hexa-acylated lipid A with one L-Ara4N. (E) 
pmrD mutant lipid A generates a major molecular ion at m/z 1796.1 when this strain is 
grown in low Mg2+, indicating presence of hexa-acylated, bis-phosphorylated lipid A. (F) 
When grown in low Mg2+, the complemented pmrD mutant produces major ions 
corresponding to single (m/z 1920.2) and double (m/z 2042.2) addition of pEtN, single 
(m/z 1927.3) addition of L-Ara4N, and addition of one pEtN and one L-Ara4N (m/z 
2051.2). Minor peaks at m/z 1717 and 1769 correspond to lipid A species lacking a 
phosphate group or bearing a shorter acyl chain, respectively. Red labels indicate species 
with a pEtN group and green labels indicate species with a L-Ara4N residue.  
 
pmrD mutant complemented lipid A modification to the same extent as the endogenous 
W3110 gene (Fig 3.2C, lanes 3, 4). This suggests that pathogenic E. coli also encode 
functional PmrD proteins that connect with the PmrAB system. 
 All results shown in Figure 3.2A were confirmed by MALDI-TOF mass 
spectrometry (Fig 3.3). Strains grown in high Mg2+ produced major molecular ions at 
approximately m/z 1797, indicating presence of hexa-acylated, bis-phosphorylated lipid 
A (Fig 3.3A, B, C), the predominant species observed in the radiolabeled profiles (Fig 
3.2A, lanes 1, 2). Wild-type E. coli grown in low Mg2+ produced several major peaks 
corresponding to three main lipid A species; hexa-acylated, bis-phosphorylated (m/z 
1797.0), pEtN-lipid A (m/z 1919.9), and L-Ara4N-lipid A (m/z 1927.1)(Fig 3.3D). 
Modified species were absent from lipid A of the pmrD- strain grown in low Mg2+, which 
only generated a major molecular ion at m/z 1796.1, corresponding to hexa-acylated lipid 
A (Fig 3.3E). This spectrum was identical to that of a pmrA mutant in low Mg2+ (Fig 3.4). 
Complementation of the pmrD mutant in low Mg2+ led to restoration of the singly 
modified lipid A species observed in the wild-type strain, as well as doubly modified 
species (pEtN2-lipid A at m/z 2042.2; pEtN/L-Ara4N-lipidA at m/z 2051.2)(Fig 3.3F).   
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Figure 3.4 MALDI-TOF mass spectrometry of negative control strain W3110 pmrA- 
This strain serves as a negative control for the W3110 pmrD- strain. (A,B) W3110 pmrA- 
produces hexa-acylated lipid A in both 10 µM (low) and 10 mM (high) Mg2+ growth 
conditions, generating major peaks at m/z 1797.0 and m/z 1796.4, respectively. Minor 
peaks at m/z 1717.1 (low)/1717.5 (high) and m/z 1769.1 (low)/1768.4 (high) correspond 
to lipid A species lacking a phosphate group or bearing a shorter acyl chain, respectively. 
 
This further demonstrates the role of pmrD in inducing PmrAB-dependent lipid A 
modification with pEtN and L-Ara4N when E. coli is grown in low Mg2+. Taken 
together, this data shows that pmrD promotes pEtN and L-Ara4N lipid A modification 
under low Mg2+ growth conditions across different E. coli strains. 
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3.2.2 pEtN/L-Ara4N lipid A modifications are PmrA-dependent, but only partially 
PhoPQ-dependent 
 Previous research has defined the epistatic relationships among PmrD, PhoPQ, 
and PmrAB in S. enterica (67, 68). We initially analyzed the 32P-labeled lipid A profiles 
of phoPQ- and pmrA- strains to explore whether similar relationships exist between these 
proteins in E. coli (Fig 3.5). It has been shown that in E. coli, pmrD expression and 
protein production are induced in low Mg2+ in a phoP-dependent manner (90). Given 
this, we expected that deletion of phoPQ from the genome would result in loss of pEtN 
and L-Ara4N lipid A modifications, since pmrD is required for addition of these groups, 
and pmrD expression is dependent on this two-component system.   
 Surprisingly, when we isolated lipid A from a phoPQ double mutant grown in low 
Mg2+ medium, it displayed a partially modified profile, containing mostly single and 
minimal double pEtN and L-Ara4N additions (Fig 3.5, lane 2). Densitometry analysis of 
the chromatographically separated radiolabeled lipid A in Figure 3.5 showed that 
approximately 40% of phoPQ- lipid A was modified versus 89% in the wild-type strain 
(Table 3.1). To confirm mutation of phoP and phoQ in the mutant, we performed semi-
quantitative RT-PCR to demonstrate that neither gene was expressed when the strain was 
grown in low Mg2+ N-minimal medium (data not shown). As a follow-up, we generated a 
 phoPQpmrD triple mutant to determine if the modifications we observed in the lipid A 
profile of the phoPQ mutant were pmrD-dependent. Indeed, we did not observe 
modifications in the phoPQpmrD- triple mutant but could restore them upon in trans 
expression of pmrD in this triple mutant (Fig 3.5, lanes 3, 4). These results imply that an  
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Figure 3.5 pEtN/L-Ara4N lipid A modifications are PmrA-dependent, but only 
partially PhoPQ-dependent 
Lipid A species observed in the profiles are depicted as cartoons; L-Ara4N, green 
hexagon and pEtN, red circle. Positive control strain WD101 produces lipid A 
constitutively modified with pEtN and L-Ara4N. E. coli W3110 strains were grown in 10 
µM Mg2+ (low) N-minimal media and radiolabeled lipid A was isolated and separated by 
TLC. 
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unknown factor or system can also activate pmrD expression, leading to completion of 
the pmrA-dependent lipid A modification pathway in the absence of phoPQ. As expected, 
a pmrA mutant was unable to modify its lipid A with pEtN and L-Ara4N and expression 
of pmrD in trans could not bypass this phenotype (Fig 3.5, lanes 5, 6). These results 
confirm that PmrD activity occurs upstream of PmrA, but challenge previous findings by 
showing that pmrD expression is not strictly PhoPQ-dependent.   
 
Table 3.1: Densitometry analysis values for Figure 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
  
 % Modified
a % Unmodifiedb 
WD101 98.52 1.48 
WT 89.42 10.58 
phoPQ- 40.06 59.94 
phoPQD- 5.49 94.51 
phoPQpmrD- + pmrD 90.56 9.44 
pmrA- 1.28 98.72 
pmrA- + pmrD 1.08 98.92 
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3.2.3 pmrD is transcriptionally active in a phoPQ mutant and its expression is not 
influenced by PmrAB 
 Given the unexpected presence of pEtN/L-Ara4N modifications in the phoPQ- 
lipid A profile, we reasoned that a PhoPQ-independent factor or system must be 
activating pmrD transcription in this double mutant. We suspected that PmrA or PmrB 
could be candidates for transcriptional control of pmrD as a means to ensure expression 
of eptA and arnT in the absence of phoPQ. Additionally, S. enterica PmrA negatively 
regulates pmrD transcription, so such an interaction would not be unprecedented (94).  
 To address this possibility, we isolated RNA from wild-type, phoPQ-, and 
phoPQpmrA and phoPQpmrB triple mutant strains grown in low Mg2+. We then 
determined expression levels of several key genes by quantitative PCR analysis (Fig 3.6). 
Ribosomal RNA rrsG showed comparable expression levels across all strains relative to 
wild-type. Expression of PhoPQ-dependent response regulator rstA was drastically 
reduced (20-fold) in the three mutant strains. Contrarily, pmrD expression was reduced 
by approximately 1.7 fold relative to wild-type, but showed 12-fold higher expression 
than rstA in the phoPQ mutant. Since rstA expression is entirely dependent on PhoPQ, 
this data demonstrates that pmrD only depends partially on PhoPQ for transcriptional 
activation in agreement with the radiolabeled lipid A profiles shown in Figure 3.5. pmrD 
expression was not significantly different among phoPQ-, phoPQpmrA-, and 
phoPQpmrB-. Next, we measured pmrA mRNA levels in the phoPQ- strain, which 
approximately matched the level observed in wild-type. Finally, PmrA-activated arnT 
showed roughly the same expression level as pmrD in phoPQ- relative to wild-type, and  
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 was expectedly almost undetectable in the triple mutant strains. These results confirm 
that pmrD is expressed in a phoPQ mutant, but also suggest that PmrA and PmrB do not 
exert transcriptional control over pmrD in the absence of phoPQ. 
 
 
 
 
Figure 3.6 pmrD expression in a phoPQ mutant is not influenced by PmrAB 
E. coli W3110 wild-type, phoPQ-, phoPQpmrA-, and phoPQpmrB- were grown in N-
minimal medium with 10 µM Mg2+ (low) and RNA was isolated. Relative expression 
levels of each gene were determined by quantitative PCR. Results are representative of 
three biological replicates.    
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3.2.4 PmrD plays a role in expression of pmrA, thereby indirectly affecting 
expression of downstream pmrA-dependent genes 
 To confirm that presence of pmrD affects PmrA-dependent gene expression as it 
does lipid A profiles, we performed RNAseq analysis on W3110 wild-type and the pmrD 
mutant strain grown in low Mg2+ compared with high Mg2+. Transcript levels for eptA, 
arnT, and pmrA all showed statistically significant upregulation in low versus high Mg2+ 
in the wild-type strain, compared with static, statistically insignificant changes in 
expression between the two Mg2+ conditions for the pmrD mutant (Table 3.2). This 
pattern also held for PmrA-dependent genes involved in synthesis of L-Ara4N (ugd, 
arnABCD).  Conversely, in both strains, a PmrA-independent but PhoP-dependent gene, 
rstA (95) was expressed at similar levels in both low and high Mg2+. This analysis was 
generated from the sequenced library of one biological replicate of each strain; a second 
biological replicate yielded similar results. RNAseq data for both biological replicates 
can be found online (http://aac.asm.org/content/59/4/2051/suppl/DCSupplemental).  
 RNAseq data were confirmed by quantitative PCR (Fig 3.7). For example, 
relative expression levels of pmrA and its downstream targets, arnT and eptA, decreased 
significantly in the pmrD- strain versus wild-type: 10-fold decline between strains for 
pmrA, 23-fold for arnT, and 72-fold for eptA. In contrast, rstA expression showed no 
significant change in expression between strains. These results demonstrate that PmrA-
dependent gene expression is robust in low Mg2+ and PmrD plays a role in expression of 
the PmrA-regulon. 
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Table 3.2: Select RNAseq data comparing gene expression in wild-type and pmrD- E. 
coli strains grown in low versus high magnesium minimal medium 
 
  
Gene 
 
Product 
 
Notes 
 
Fold 
change in 
WT 
WT  
P value 
Fold 
change in 
pmrD- 
pmrD- P 
value 
arnT 
4-amino-4-deoxy-L-arabinose 
transferase pmrA/pmrD-dependent 6.69 <10-9 1.13 0.88 
eptA 
Phosphoethanolamine 
transferase pmrA/pmrD-dependent 32.05 <10-9 1.54 0.6 
pmrA 
DNA-binding response 
regulator in two-component 
regulatory system with pmrB pmrA/pmrD-dependent 7.58 <10-9 -1.25 0.45 
ugd UDP glucose 6-dehydrogenase pmrA/pmrD-dependent 20.22 <10-9 1.47 0.24 
arnA 
(yfbG) 
fused UDP-L-Ara4N 
formyltransferase/ UDP-
glucouronic acid C-4'-
decarboxylase pmrA/pmrD-dependent 10.2 <10-9 -1.32 0.31 
arnB 
(yfbE) 
UDP-4-amino-4-deoxy-L-
arabinose oxoglutarate 
aminotransferase pmrA/pmrD-dependent 69.60 <10-9 -1.89 0.11 
arnC 
(yfbF) 
undecaprenyl phosphate 4-
deoxy-4-formamido-L-
arabinose transferase pmrA/pmrD-dependent 110 <10-9 -2.24 0.02 
arnD 
(yfbH) 
4-deoxy-4-formamido-L-
arabinose-
phosphoundecaprenol 
deformylase pmrA/pmrD-dependent 18.4 <10-9 -1.41 0.49 
rstA 
DNA-binding response 
regulator in two-component 
regulatory system with RstB 
phoP-dependent 
pmrA/pmrD-independent 52 <10-9 64.19 <10-9 
gyrA gyrase subunit A 
Housekeeping gene 
pmrA/pmrD-independent -1.8 <10-9 -1.53 <10-9 
rpsD ribosomal protein 
Housekeeping gene 
pmrA/pmrD-independent -1.3 <10-9 -1.62 <10-9 
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Figure 3.7 pmrD impacts transcription of pmrA and its downstream genes 
Relative gene expression of pmrA, arnT, eptA, pmrD and rstA when E. coli W3110 wild-
type and pmrD mutant were grown in N-minimal medium with 10 μM Mg2+ (low). 
Results are representative of 3 technical replicates. 
 
3.2.5 Polymyxin B resistance in E. coli is pmrD-dependent in low Mg2+ but not in 
mildly acidic pH 
 pEtN and L-Ara4N lipid A modifications are especially important for bacterial 
survival in an environment where host-produced CAMPs are present. These chemical 
groups mask the negative charge of the lipid A molecule imparted by the phosphates that 
flank the glucosamine disaccharide. Thus, the overall charge of the bacterial cell surface 
becomes more neutral and better repels positively charged antimicrobial peptides than an 
unmodified outer membrane (54, 96)(Fig 3.1B). We reasoned that an E. coli pmrD 
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 mutant would survive poorly with respect to wild-type when exposed to the CAMP 
polymyxin B due to the inability of the pmrD mutant to incorporate protective lipid A 
modifications (Fig. 3.2A).  
 Accordingly, we determined the ability of wild-type, pmrD-, and complemented 
pmrD- strains to survive in various concentrations of polymyxin B. To start, we grew 
these strains in low Mg2+ N-minimal medium (Fig 3.8A), the same condition known to 
induce pEtN/L-Ara4N modifications in wild-type. Under these parameters, we noticed a 
statistically significant (41.4%) decline in survival between wild-type and the pmrD 
mutant after a 1-hour exposure to 2.5 µg/ml polymyxin B. This difference was no longer 
observed upon expression of pmrD in the mutant strain. Repetition of the same assay 
conditions with 5 µg/ml polymyxin B increased the disparity between wild-type and the 
pmrD mutant even further, with a statically significant 68% decline in survival between 
the two strains that could also be reversed by overexpression of pmrD (Fig 3.8A).  
 We next determined survival at mildly acidic pH 5.8, a signal that induces pEtN 
and L-Ara4N lipid A modifications regardless of Mg2+ concentration and independently 
of the PhoPQ system (88, 89). While both PmrB and PhoQ can be activated at pH 5.8, the 
PmrA-dependent lipid A modifications seen in this condition are likely due 
predominantly to activation of PmrB since they are observed even when PhoQ is 
repressed (40, 53, 67, 88). Therefore, since this condition autonomously activates PmrAB 
and thus downstream lipid A modifications, it follows that presence of pmrD should be 
irrelevant to bacterial survival since its function is bypassed. Wild-type and the pmrD   
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Figure 3.8 pmrD plays a role in polymyxin B resistance 
(A) E. coli W3110 wild-type, pmrD-, and the complemented pmrD mutant were grown in 
N-minimal medium with 10 µM Mg2+ (low) at pH 7.5. Strains were challenged with 0, 
2.5, or 5 µg/ml polymyxin B or phosphate buffered saline for 1 hour, serially diluted, and 
plated for survival. The wild-type strain survived at 98.7% and 78.75% in 2.5 and 5 
µg/ml polymyxin B, respectively. The pmrD mutant survived at 57.3% and 10.68% when 
exposed to 2.5 and 5 µg/ml polymyxin B, respectively. (B) The same experiment 
described in panel A was performed at pH 5.8. Wild-type survived at 95.8% and 105.6% 
in 2.5 and 5 µg/ml polymyxin B, respectively. The pmrD mutant survived at levels that 
were not statistically significantly different from wild-type: 106% and 111.8% in 2.5 and 
5 µg/ml polymyxin B, respectively. Results are representative of 3 biological replicates. 
(* = p < 0.05)  
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mutant did not show a statistically significant difference in survival when grown at pH 
5.8 in low Mg2+ at either 2.5 or 5 µg/ml polymyxin B (Fig 3.8B). The survival data 
presented here clearly illustrate the necessity of pmrD for polymyxin B resistance when 
Mg2+ is limiting, and underscore that its activity occurs upstream of PmrAB.  
3.3 DISCUSSION 
 A rapid response is crucial for bacterial survival when environmental conditions 
change. For gram-negative organisms, biochemical modification of outer membrane 
components can result in altered membrane characteristics tailored to defend against 
specific external insults. The lipid A portion of LPS is a common target for modification, 
as modulation of its charge and subtleties of its structure can drastically impact 
membrane integrity (2, 39, 48, 73).   
 When abundant in the environment, divalent cations such as Mg2+ and Ca2+ bind 
to LPS, creating ionic bridges between neighboring negative lipid A molecules; this 
contributes considerable stability to the outer membrane (39). Conversely, when divalent 
cations are limited, absence of this crucial reinforcement results in a vulnerable 
membrane and initiation of a bacterial response to address its weakened defenses (40). In 
Salmonella, this signal is sensed by PhoQ, and subsequently propagated to the PmrAB 
system via PmrD; this cascade ultimately leads to activation of enzymes EptA and ArnT 
that add polar residues to the lipid A (63, 65). While limiting Mg2+ is an important signal 
that negatively affects the gram-negative bacterial cell, it is unclear if Salmonella and E. 
coli encounter environments specifically depleted of Mg2+, particularly in the course of 
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infection (55, 97–99). Although decoration of lipid A with pEtN and L-Ara4N results in a 
stronger membrane barrier that can be advantageous in low Mg2+, the primary benefit of 
these positively-charged modifications is more likely linked with protection against 
CAMPs (60, 64). It is thought that low Mg2+ promotes activation of PhoQ in a manner 
that mimics activation of this sensor kinase by CAMPs. CAMPs compete with and 
displace divalent cations from PhoQ, allowing it to assume an active conformation; low 
Mg2+ concentrations may similarly promote this active conformation by allowing PhoQ 
to remain free from the membrane (55). In any case, the results presented here clearly 
demonstrate that this lipid A modification machinery is robustly activated by low Mg2+ 
growth conditions, which suggests there may exist an evolutionary pressure to modify the 
membrane under this condition.  
  Based on our research, this circuitry in E. coli is more complicated than 
previously thought. There has been a long-held belief in the field that cross talk does not 
occur between PhoPQ and PmrAB in this organism, based on one group’s finding that 
PmrA-dependent genes are not transcribed when the organism is grown in PhoPQ-
activating low Mg2+ (90). Previous findings from our laboratory, however, detected the 
presence of pEtN and L-Ara4N additions on lipid A isolated from wild-type E. coli 
grown in 10µM magnesium (89). Further, Hagiwara et al. suggested that PhoPQ and 
PmrD are necessary for full transcriptional induction of PmrA-dependent genes (100). 
These data are confirmed in the current work, which also highlight the necessity of E. 
coli pmrD for these PmrAB-dependent lipid A modifications, expression of PmrA-
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dependent genes, and polymyxin B resistance in low Mg2+ conditions. Therefore, while 
previous research has largely labeled E. coli PmrD as an inactive two-component system 
connector protein, our findings demonstrate that it is active and necessary for lipid A 
modification.  
 Importantly, we uncovered a second, as yet unidentified system or factor that 
activates pmrD under low Mg2+ conditions in the absence of phoPQ. pEtN and L-Ara4N 
were clearly integrated into lipid A of the phoPQ double mutant (Fig 3.5), which was 
surprising given that pmrD expression had previously been shown to be strictly PhoP-
dependent in E. coli (90). This phenotype could result either from activation of pmrD in a 
PhoPQ-independent manner, or a second connector protein having redundant activity 
with PmrD. Given that subsequent deletion of pmrD from the phoPQ mutant removes 
these modified species from the profile and evidence that pmrD is transcriptionally active 
in the phoPQ mutant (Fig 3.6), we conclude that the former possibility is more likely. It 
is difficult to predict whether this second system contributes to lipid A modification in 
the wild-type strain, or if it functions predominantly when PhoPQ is absent. Progress is 
ongoing in our laboratory to define the molecular machinery behind these findings. In all, 
these results suggest that E. coli has wired a second route to activate pmrD in the absence 
of its primary transcriptional activator PhoP. This underlines the importance of pEtN/L-
Ara4N modifications in low Mg2+ and maintains the necessity of PmrD in their addition 
to lipid A.   
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 Our findings introduce a new layer of complexity into the PhoPQ-PmrD-PmrAB 
story. This cascade has been characterized extensively in S. enterica, but the current work 
focuses on the dynamics of this system in E. coli. Our results strongly support that: 1) 
PmrD maintains the PhoPQ-PmrAB connection in this organism, and 2) a second system 
can respond to low Mg2+ in the absence of phoPQ to ensure activation of PmrD and 
fulfillment of the lipid A modification pathway. In all, these findings expand the 
repertoire of signals integrated and machinery employed by E. coli to respond to and 
defend against CAMPs.  
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Chapter 4: Conclusion 
4.1 FUTURE DIRECTIONS AND CONCLUDING THEMES   
Decades of elegant research have described the structure of endotoxin, its 
biosynthesis pathway, and its role in activation of the innate immune response. Within 
each of these topics, a considerable amount of diversity has been discovered across this 
broad group of bacterial organisms: the precise chemical composition of lipid A 
produced, alternative mechanisms or properties of biosynthetic enzymes, and differential 
activation of TLR4/MD2 by lipid A structural variants, to name a few. The findings 
explained in these chapters build on this diversity with two new pieces of knowledge: 
introduction of a unique Raetz pathway acyltransferase in Epsilonproteobacteria 
including H. pylori, and reinterpretation of conditional post-translational control of lipid 
A modifications in E. coli.  
The story of LpxJ is compelling because it uncovers a large and previously 
unknown family of acyltransferases, many of which may act in place of LpxM during 
lipid A biosynthesis in their respective organisms. This is certainly the case in three 
Epsilonproteobacteria, whose LpxJ enzymes can accept substrates of various acylation 
and Kdo-sylation states (25). In the absence of a crystal structure for both LpxJ and 
LpxM, it is difficult to provide a structural or mechanistic rationale for this flexibility. 
Future work should explore the role of inner membrane lipid A flippase, MsbA, in 
governing LpxJ substrate specificity since it is next in line to receive lipid A on its way to 
the cell surface. Given that LpxJ shares almost no homology with LpxM and resides in an 
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entirely different enzymatic family, it would be extremely interesting to determine an 
evolutionary explanation for this branching event. 
Our findings for E. coli PmrD disprove a long-held belief in the field: that PmrD 
in this organism does not allow connection between the PhoPQ and PmrAB TCSs. A 
simple analysis of the lipid A profiles of wild-type, a pmrD mutant, and complemented 
pmrD mutant was employed to conclude definitively that PmrD does promote this 
connection in E. coli. Beyond this, existence of a previously unknown factor that 
activates pmrD expression in the absence of PhoPQ was serendipitously discovered (70). 
The primary focus of future work on this topic should be to find the genetic identity of 
this factor and characterize its relationship with pmrD, which may be achieved by a 
combination of RNAseq, Tn-seq, and lipid A profile analysis. 
Regulation of lipid A modifications by small proteins like PmrD at the post-
translational level turns out to be a fairly common theme in E. coli and other gram-
negatives. Perhaps knowledge of these systems can be informative in finding and 
understanding the mystery activator of pmrD. For example, LpxT is the enzyme 
responsible for generating the 1-diphosphate species commonly found in the E. coli K-12 
outer membrane; it does this by transferring a phosphate group to the 1-phosphate of lipid 
A from carrier lipid undecaprenyl pyrophosphate (89, 101, 102). LpxT activity can be 
repressed by small peptide, PmrR, which is activated by PmrAB in high Fe3+ conditions 
(103). Regulation of this lipid A modifying enzyme can be important in high Fe3+: when 
a negatively-charged phosphate group is not added at the 1-phosphate, EptA is free to 
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transfer a positively charged pEtN to this site (89). As a result of this enzymatic trade-off, 
the net negative charge of the outer membrane decreases, which limits its association 
with Fe3+, and thereby reduces PmrAB activation in a negative feedback loop (89, 103). 
Inner membrane sensor histidine kinase, PhoQ is also subject to post-translational 
modification by several small proteins in E. coli. For instance, TCS EvgAS activates a 65 
amino acid inner membrane protein, SafA (formerly known as B1500), which then 
complexes with and activates PhoQ (104). This connection is thought to diversify 
survival strategies in an acidic environment, as EvgAS is likely involved in the acid 
resistance response. MgrB is another small hydrophobic protein present in E. coli, S. 
typhimurium, and Y. pestis. Activated by PhoPQ, its function is to repress PhoQ activity 
at the inner membrane, thus providing negative feedback and fine tuning the response of 
this TCS (105).  
More recently, PmrB of the PmrAB TCS has been demonstrated to be a phospho-
donor for quorum sensing response regulator QseB in the absence of its cognate sensor, 
QseC (106). PmrB can phosphorylate QseB, but is inefficient at dephosphorylating it. 
Therefore, in absence of QseC, QseB is overactive, leading to aberrant transcription 
cascades and loss of virulence. These studies underscore that small proteins are a 
common mechanism promoting communication between TCSs, which often occurs in 
multi-layered networks. 
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4.2 THE NEXT STEPS FOR LIPID A: ANTIBIOTICS AND THERAPEUTICS 
A number of fundamental open questions remain in the lipid A field, which are 
becoming increasingly important as the world recognizes the serious threat of antibiotic 
resistant gram-negative infections. At the top of the list, the reason for the essential nature 
of lipid A still remains elusive in the field, while a growing number of gram-negatives 
appear to be viable when lipid A biosynthesis is interrupted under specific growth 
conditions. 
For instance, both Neisseria meningitidis and Moraxella catarrhalis are able to 
survive in the laboratory with a lipooligosaccharide (LOS)-deficient outer membrane.  
Instead of producing LPS, some gram-negatives make LOS, an outer membrane 
glycolipid that does not contain O-antigen and therefore only has core sugars attached to 
the lipid A anchor (107). Laboratory strains of N. meningitidis and M. catarrhalis without 
detectable LOS were found to have mutations in lpxA, which encodes the first enzyme of 
lipid A biosynthesis (Fig 1.2) and is almost always lethal when mutated in gram-
negatives (10, 108, 109). Recently, an LOS-deficient clinical isolate of N. meningitidis 
was identified with a causative missense mutation in the gene encoding the fourth Raetz 
pathway enzyme, LpxH (110). Further, multi-drug resistant nosocomial pathogen 
Acinetobacter baumannii can spontaneously lose its LOS in the presence of high 
concentrations of the CAMP colistin by inactivation of lpxA, lpxC, or lpxD (Fig 
4.1A)(111, 112). Loss of LOS has also been shown to accompany colistin-resistance of 
multiple A. baumannii clinical isolates due to nonsense mutation of lpxA or insertion 
mutation of lpxD (Fig 4.1B)(112).  Although loss of LOS/LPS is regarded as an extreme  
 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.1: Acinetobacter baumannii can survive without LOS in the laboratory and the 
clinic 
This figure has been adapted from Jennifer H. Moffatt et al. 2010. Antimicrob. 
Agents Chemother. 54:4971–4977. 
(A) Transmission electron microcrographs of colistin-susceptible A. baumannii strain 
ATCC 19606 (left) and colistin-resistant lpxA mutant 19606R (right). Arrows indicate the 
presence of intact inner and outer membranes in both strains, suggesting that 19606R 
constructs an outer membrane despite loss of LOS. (B) Carbohydrate-specific silver stain 
of proteinase-K treated whole cell lysates. The profile of a colistin-sensitive clinical 
isolate from a human bronchoalveolar lavage fluid sample contains a band representing 
LOS that migrates at approximately 8kDa. This band is missing from two genetic 
derivatives of this clinical strain characterized by colistin resistance.  
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 measure to achieve antibiotic resistance, it can clearly occur in select organisms via 
multiple mutations in the lipid A biosynthesis pathway that are typically lethal. These 
results forecast a coming shift for the clinical community that will require creative drug 
combinations to overcome this new resistance mechanism. 
Acquisition of antibiotic resistance is a widespread and startlingly rapid process 
that is quickly becoming the next global public health emergency. Development of 
effective lipid A biosynthesis inhibitors is now a top priority for the research and clinical 
communities; with the exception of the few organisms that do not require LPS, most 
gram-negatives would be extremely sensitive to such an antibiotic. Further, given that 
each enzyme in the pathway is essential, a bacterium would need to make drastic 
unprecedented biochemical changes to achieve resistance to such a toxic compound.   
One promising target is LpxC, which catalyzes deacetylation of UDP-3-O-(acyl)-
N-acetylglucosamine in the second step of the Raetz pathway (11). Although second 
sequentially, LpxC performs the first committed step of lipid A biosynthesis, as the first 
step catalyzed by UDP N-acetylglucosamine acyltransferase LpxA is energetically 
unfavorable (113). Further, LpxC is well-conserved across gram-negatives and does not 
share homology with any mammalian proteins, properties that make it an ideal target for 
a highly-specific antibiotic with few off-target effects (114). Resolution of the LpxC 
crystal structure has allowed elucidation of its catalytic mechanism and substrate binding 
chemistry (114, 115). In the years since, several potent inhibitors have been identified 
that act by competing with the substrate, UDP-3-O-(R-3-hydroxymyristoyl)-GlcNAc to 
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block catalysis (Fig 4.2A). Though none of these are currently ready for clinical use, 
progress is ongoing to optimize potency, minimize unintended targets, and increase the 
range of organisms against which these compounds are effective. Similar approaches in 
drug development could also be taken with essential enzymes further down the pathway, 
including late acyltransferase LpxJ in H. pylori. While an exact or comparable crystal 
structure is missing for this particular enzyme, a high-throughput small molecule screen 
could be used to discover inhibitors. Such a drug could be extremely valuable in fighting 
H. pylori infection, as it would prevent completion of lipid A biosynthesis, leaving the 
bacterium to die due to lack of a viable outer membrane. 
 While it is crucial to discover lipid A biosynthesis inhibitors in the fight against 
antiobiotic resistance, lipid A can also be exploited to help in prevention of other diseases 
in the form of a vaccine adjuvant. Monophosphorylated lipid A (MPL) is an FDA-
approved adjuvant and structural variant of lipid A that stimulates a safe and effective 
inflammatory cytokine profile for boosting the immunogenicity of vaccines (Fig 
4.2B)(116). Building on this, a library of E. coli strains producing one of two “template” 
lipid A structures (Fig 4.2C) and expressing combinations of various lipid A modification 
enzymes was recently engineered for intended use in both therapeutic and pharmaceutical 
applications (8). The strains in this library produce a range of lipid A structures that elicit 
a corresponding diversity in cytokine response. This tool demonstrates that even the 
subtlest structural alterations can dramatically change the physiological response to lipid 
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Figure  4.2: Molecular engineering applications in lipid A studies   
(A) Structure of LpxC inhibitor CHIR-090 (117). This hydroxamate compound follows a 
two-step slow, tight-binding inhibition of LpxC and is bactericidal for a wide range of 
gram-negative pathogens. (B) Chemical structure of 3-O-deacyl-4′-monophosphoryl lipid 
A, the primary lipid A species present in the FDA-approved vaccine adjuvant, MPLTM. 
(C) Lipid A structural templates 1 and 2 were used as frameworks for modification 
enzymes to build a combinatorially engineered lipid A library for therapeutic use (8). 
Expression of LpxJ in place of LpxM would create a third template to add diversity to 
this library.   
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A in a manner useful for clinical and industry applications. Following this idea, LpxJ 
could conceivably be used to make a unique lipid A template to introduce diversity into 
this library. If expressed in place of E. coli LpxM, LpxJ would allow for synthesis of 
penta-acylated lipid A with a 3′- (instead of 2′-) secondary acyl chain (Fig 4.2C). Given 
the wide range of immunogenicity elicited by the current library, it is likely that adding a 
third template could refine and resolve the spectrum even further.   
Another intriguing avenue for the future of lipid A related studies is exploring the 
concept of host-specific TLR4 polymorphisms that affect an individual’s immune 
reaction to lipid A and its structural variants. For example, a common polymorphism 
causes a change in identity for two residues within the TLR4 protein: amino acid 299 
from aspartate to glycine, and residue 399 from threonine to isoleucine (118). These 
amino acid changes are thought to affect TLR4 dimerization and are associated with 
overall TLR4 hyporesponsiveness and increased susceptibility to infection with gram-
negative bacteria and septic shock (118–120). The decreased reactivity displayed by this 
TLR4 variant is even more pronounced upon stimulation with MPL versus bis-
phosphorylated lipid A, suggesting it is sensitive to differences in precise lipid A 
structure (120). It would be extremely interesting to determine the impact of other 
modifications such as variation in acyl chain length and number, and presence of groups 
like pEtN and L-Ara4N. 
The findings presented here help stretch the arms of endotoxin into many exciting 
and potentially game-changing arenas for the future of medicine. In a few years, lipid A 
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may even be able to put its stamp on the world’s first HIV and cancer vaccines. For all 
these reasons, it seems inevitable that this bioactive molecule will remain in the 
international research spotlight for many years to come.  
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Chapter 5: Experimental Procedures 
5.1 MATERIALS AND METHODS 
5.1.1 Bacterial strains and growth conditions 
The bacterial strains, plasmids, and oligonucleotides used in this study are listed in 
Section 5.2. Primary plate cultures of E. coli were grown from glycerol stock on LB agar 
or broth medium or N-minimal media (0.1M Bis-Tris pH 7.5 or 5.8, 5 mM KCl, 7.5 mM 
(NH4)2SO4, 0.5 mM K2SO4, 1 mM KH2PO4, 0.10% casamino acids, 0.20% glucose, 
0.0002% thiamine, 15 µM FeSO4, 10 µM or 10 mM MgSO4) at 37°C with appropriate 
antibiotics; ampicillin (100 µg/ml), kanamycin (30 µg/ml), or chloramphenicol (30 
µg/ml). Primary plate cultures of H. pylori were grown from glycerol stock on blood agar 
medium containing vancomycin (10 µg ml-1) at 37 °C for 36 to 60 h in a microaerobic 
atmosphere (5% O2, 10% CO2, 85% N2). 
5.1.2 Isolation and analysis of lipid A species from 32Pi-labeled cells 
Various strains were grown either in LB or N-minimal medium at 37 °C with 2.5 µCi/ml 
32Pi (Perkin Elmer). Bacteria were harvested at OD600 ~0.8 and washed with 5 ml 
phosphate-buffered saline. 32P-labeled lipid A was isolated as described previously and 
spotted onto a Silica Gel TLC plate (~10,000 cpm per lane)(27). Lipids were separated 
using a chloroform, pyridine, 88% formic acid, and water solvent system (50:50:16:5, 
vol/vol). TLC plates were exposed to a PhosphorImager screen (Kodak) and analyzed 
using a Bio-Rad Molecular Imager in conjunction with Quantity One software. 
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5.1.3 Mass spectrometry of lipid A species 
Matrix assisted laser desorption-ionization time-of-flight (MALDI TOF) mass 
spectrometry was performed using a MALDI-TOF/TOF mass spectrometer (ABI 4700 
Proteomics Analyser) as previously described (22). Ultraviolet photodissociation 
(UVPD) mass spectrometry was performed in the negative mode on a Thermo Scientific 
Orbitrap Elite mass spectrometer (Bremen, Germany) equipped with a 193 nm ArF 
excimer laser from Coherent (ExiStar XS, Santa Clara, CA) using a recently described 
setup (121).  Lipid A samples were prepared for UVPD-MS by diluting samples to 
approximately 1 µM with 50:50 methanol:chloroform (Sigma Aldrich, St. Louis, MO). 
Lipid A solutions were directly infused via electrospray ionization using a potential of 4 
kV and a sheath gas flow rate of 10 arbitrary units. All UVPD mass spectra were 
acquired in the Orbitrap mass analyzer using a resolution of 15,000 and a total of ten 6 
mJ pulses per scan. 
5.1.4 Construction of genetic mutant and chromosomal complementation of H. 
pylori J99 jhp0255 (lpxJHp). 
Vectors and oligonucleotides used in Chapter 2 are listed in Section 5.2, Tables 5.1 and 
5.2, respectively. The jhp0255 coding sequence, including 1,369 bp upstream and 1,000 
bp downstream was amplified by PCR (primers 1 and 2, Table 5.2) from H. pylori J99 
genomic DNA using Pfu Turbo (Stratagene) according to the manufacturer’s instructions. 
The resultant DNA fragment was digested with NheI and XhoI, gel purified, and cloned 
behind the T7lac promoter in vector pET21a. Next, a kanamycin resistance cassette was 
obtained by PCR (primers 5 and 6, Table 5.2) from the E. coli-H. pylori shuttle vector, 
 
 
84 
pHel3, and inserted into pET21a containing jhp0255. This was accomplished by 
encoding BamHI and NotI restriction sites on the pET21a:jhp0255 vector via inverse 
PCR (primers 3 and 4, Table 5.2), then digesting the kanamycin fragment and 
pET21a:jhp0255 vector with BamHI and NotI. This allowed excision of the jhp0255 
coding sequence and subsequent replacement/ligation with the kanamycin cassette. The 
resulting plasmid (jhp0255KO+/-) containing an interrupted jhp0255-coding gene, was 
transformed into H. pylori J99 by natural transformation (122). Due to the essential 
nature of the gene, knock-out attempts were unsuccessful (see Results).  
 Chromosomal complementation was achieved by cloning jhp0255 into vector 
pET0634comp. This plasmid allows for insertion of a chosen coding sequence into the 
rdxA locus on the genome, inactivating the rdxA gene. RdxA is a nitroreductase that 
converts metronidazole from an inactive pro-drug to its active form, so inactivation of the 
gene renders the bacterium resistant to metronidazole (22, 123). The jhp0255 coding 
sequence was amplified by PCR (primers 13 and 14, Table 5.2) from H. pylori J99 
genomic DNA using Pfu Turbo (Stratagene) according to the manufacturer’s instructions. 
The resultant DNA fragment was digested with BamHI and EcoRI, gel purified, and 
ligated to BamHI/EcoRI, alkaline phosphatase-treated pET0634comp vector. The 
completed plasmid (pET0634compjhp0255) was transformed into wild type H. pylori J99 
by natural transformation and resistant colonies were selected on blood agar plates 
containing 10 µg ml-1 metronidazole. Resistant colonies were restreaked on fresh 
metronidazole plates and successful insertion of the complementation cassette at the rdxA 
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locus was confirmed by PCR of genomic DNA (primers 15 and 16, Table 5.2). With a 
second copy of jhp0255 now present at the rdxA locus, we proceeded to prove that we 
could then knock out jhp0255 at its normal locus. To achieve this, we transformed 
plasmid jhp0255KO+/- into the rdxA::jhp0255 strain by natural transformation. Resistant 
colonies were obtained when bacteria were plated on blood agar containing 30 µg ml-1 
kanamycin. Colonies were restreaked on fresh kanamycin plates and successful insertion 
of the kanamycin cassette at the jhp0255 locus was confirmed by PCR of genomic DNA 
(primers 17 and 18, Table 5.2). 
5.1.5 Generation of low-copy plasmids for expression of late acyl transferases from 
Epsilonproteobacteria and the E. coli pmrD gene 
Vectors and oligonucleotides used in Chapter 2 are listed in Section 5.2, Tables 5.1 and 
5.2, respectively. The acyltransferases of H. pylori J99 (jhp0255, primers 7 and 8, Table 
5.2), C. jejuni 81-176 (cjj81176_0482, primers 9 and 10, Table 5.2), and W. succinogenes 
(ws1775, primers 11 and 12, Table 5.2) were cloned into vector pET21a (Novagen) 
behind the T7lac promoter. The PCR product from jhp0255, amplification was digested 
with NdeI and BamHI, and cjj81176_0482 and ws1775 were digested with NdeI and SalI. 
Digested PCR products were ligated individually overnight into pET21a at 16 °C using 
T4 DNA ligase (New England BioLabs) to generate pET21ajhp0255, 
pET21acjj81176_0482, pET21aws1775. Next, each plasmid was cut with XbaI and XhoI, 
excising the respective gene coding regions along with a ribosomal binding site. The 
resultant fragments were ligated individually into pWSK29 to give pWSK29jhp0255, 
pWSK29cjj81176_0482, and pWSK29ws1775 for expression of the acyltransferases in E. 
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coli. The three vectors were transformed into XL-1 Blue (Stratagene) for propagation, 
then BN2 and MKV15b for radiolabeling and mass spectrometry experiments, 
respectively.  
 Vectors and oligonucleotides used in Chapter 3 are listed in Section 5.2, Tables 
5.3 and 5.4, respectively. W3110 pmrD was cloned out of E. coli genomic DNA (primers 
1 and 2, Table 5.4). The resultant fragment was digested with NdeI and BamHI and 
ligated overnight into pET21a at 16 °C using T4 DNA ligase to generate pET21apmrD. 
Next, the plasmid was cut with XbaI and XhoI, excising the pmrD coding region along 
with a ribosomal binding site, which were ligated into pWSK29 to give pWSK29pmrD. 
The vector was transformed into XL-1 Blue (Stratagene) for propagation and various K-
12 strains for expression of pmrD. Based on consistency in sequence between strains, 
primers 1 and 2 (Table 5.4) were used to clone pmrD from strain W3110, MG1655, 
EHEC, and ETEC. All cloned vectors were sequenced prior to use. 
5.1.6 Preparation of radiolabeled lipid substrates for in vitro enzymatic assays 
The substrate [4′-32P] lipid IVA was prepared from 125 µCi of [γ-32P]ATP and the tetra-
acyl-disaccharide 1-phosphate lipid acceptor, using the overexpressed 4′ kinase in the 
membranes of E. coli strain BLR(DE3)/pLysS/pJK2 as previously described (58). Kdo2-
[4′-32P] lipid IVA was generated by adding purified E. coli Kdo transferase (KdtA) 
immediately following the 4′ kinase, as previously described (124). Following the Kdo 
transfer reaction, membranes from E. coli strain BLR(DE3)HtrB and E. coli strain 
BLR(DE3)/MsbB as well as C12:0-acyl carrier protein (ACP) were added to generate 
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Kdo2-[4′-32P] lipid A, as previously described (58). Kdo2-lauroyl-[4′-32P] lipid IVA was 
generated as Kdo2-[4′-32P] lipid A, with the omission of BLR(DE3)/MsbB membranes 
and addition of C12:0-ACP at a 1:1 molar ratio. 
5.1.7 In vitro assay of LpxJHp, LpxJCj, and LpxJWs activities. 
All enzymes were assayed under optimized conditions in a 10 µl reaction mixture 
containing 50 mM HEPES, pH 7.5, 0.2% Triton X-100, 2.5 µM lipid A substrate ([4′-32P] 
lipid IVA, Kdo2-[4′-32P] lipid IVA, Kdo2-lauroyl-[4′-32P] lipid IVA, or Kdo2-[4′-32P] lipid 
A at ~5,000 cpm nmol-1) with either 5 µM ACPSH, C12:0-ACP/CoA, C14:0-ACP/CoA, 
C16:0-ACP/CoA, C18:0-ACP/CoA. Washed BN2 membranes expressing each late 
acyltransferase were used in the following concentrations as enzyme source: LpxJHp 0.01 
mg ml-1, LpxJCj 0.01 mg ml-1, LpxJWs 0.005 mg ml-1. Reactions were incubated at 30 °C 
for 30 minutes, terminated by spotting 4.5 µl onto Silica Gel thin-layer chromatography 
(TLC) plates, and dried under cool air for 20 min. Reaction products were separated 
using a chloroform, pyridine, 88% formic acid, and water solvent system (30:70:16:10, 
vol/vol). TLC plates were exposed to a PhosphorImager screen and analyzed using a Bio-
Rad Molecular Imager in conjunction with Quantity One software.  
5.1.8 Preparation of cell-free extracts, double-spun cytosol, and washed membranes 
200 mL of E. coli cultures were grown to an A600 of ~1.0 at 37 °C and harvested by 
centrifugation at 10,000 x g for 10 min at 4 °C. Cell free extracts, membrane-free cytosol, 
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and stored in aliquots at -20 °C (58). Protein concentration was determined by the 
bicinchoninic acid assay method using bovine serum albumin as the standard (125). 
5.1.9 Generation of E. coli mutants 
Strains and oligonucleotides used in Chapter 3 are listed in Section 5.2, Tables 5.3 and 
5.4, respectively. All mutant strains with the exception of W3110 phoPQ- were generated 
by P1 vir phage transduction from individual Keio collection mutants for pmrD, pmrA, or 
pmrB as previously described (126, 127).  These strains include: W3110 pmrD-, pmrA-, 
phoPQpmrD-, phoPQpmrA-, and phoPQpmrB-, and MG1655 pmrD-. Candidate colonies 
were evaluated using a primer within the kanamycin cassette of each mutation (primer 6, 
Table 5.4) and an outside primer specific to an up- or downstream neighboring gene 
(primer 3 for pmrD, primer 4 for pmrA, and primer 5 for pmrB, Table 5.4). W3110 
phoPQ- was generated in the DY330 strain based on the λ Red recombination system 
(128) using primers 18 and 19 (Table 5.4) as previously described (89). 
5.1.10 Total RNA Isolation and Quantitative RT-PCR 
E. coli strains were grown overnight in LB liquid culture. The following day, bacteria 
were spun down, washed with N-minimal media without Mg2+ or iron, and inoculated at 
OD600 0.1 into N-minimal media pH 7.5 containing 10 µM MgSO4. Cultures were grown 
to approximately OD600 0.6, then cells were harvested and total RNA extracted with the 
Qiagen RNeasy Mini kit followed by treatment with RNase free DNase (Qiagen). cDNA 
synthesis was performed with the High Capacity cDNA Reverse Transcription Kit (AB 
Applied Biosystems).  The quantification of target genes by qPCR was performed using 
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2X SYBR® Green PCR master mix (AB Applied Biosystems) and specific primers for 
each transcript (Section 5.2, Table 5.4).  Data analysis was performed using ABI 7900HT 
Fast Real Time PCR System and the Software Sequence Detection Systems (SDS) 
version 2.4 (AB Applied Biosystems).  The relative expression ratio of the target 
transcript was calculated in comparison to the gyrB transcript as the reference gene 
following the Pfaffl method (129). 
5.1.11 Construction of Illumina libraries, RNA sequencing, and data analysis 
Total RNA was depleted of rRNA using the Ribo-Zero™ rRNA Removal Kit for gram-
negative bacteria (Epicentre). Illumina libraries were built from rRNA-depleted total 
RNA using the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina®. 
RNA sequencing data were mapped to the E. coli W3110 reference genome in CLC Bio 
Genomics Workbench software and expression values were determined using RPKM. 
Baggerly’s test on proportion of counts between samples determined a p-value and 
weighted proportions fold change per gene (130).  A weighted proportion absolute 
change of 4-fold and an FDR corrected p-value of ≤0.01 were used as cutoffs as 
previously described (131). Reads mapping to the last 21 bp of the pmrD gene in the 
W3110 pmrD mutant were discarded based on use of the Keio pmrD mutant as the source 
of the W3110 mutant strain.  
5.1.12 Polymyxin B survival assays 
E. coli strains were grown overnight in LB liquid culture. The following day, bacteria 
were spun down, washed with N-minimal media without Mg2+ or iron, and inoculated at 
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OD 0.1 into N-minimal media of one of the following conditions: 1) pH 7.5, 10 µM 
MgSO4 or 2) pH 5.8, 10 µM MgSO4. Cultures were grown to OD600 0.6 and split in half; 
one half of the culture was treated with either 2.5 or 5 µg/ml polymyxin B, and the other 
half was treated with an equivalent volume of PBS. Cultures were incubated at 37 °C for 
1 hour then serially diluted and plated on LB agar. Survival values were calculated by 
dividing the number of bacteria after treatment with polymyxin B relative to those 
incubated in the presence of PBS and then multiplied by 100.   
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5.2 BACTERIAL STRAINS AND OLIGONUCLEOTIDES 
Table 5.1: Bacterial strains and plasmids used in Chapter 2 
 
Strains 
 
Genotype or Description 
Source or 
Reference 
H. pylori   
J99 Wild type ATCC 700824 
 
J99/rdxA::jhp0255 J99 complemented with jhp0255 (lpxJHp) at 
rdxA locus 
This work 
J99/rdxA::jhp0255, 
jhp0255::kanR 
J99 complemented with jhp0255 (lpxJHp) at 
rdxA locus, kanamycin resistance cassette 
in jhp0255 (lpxJHp) 
 
This work 
C. jejuni   
81-176 Serotype HS: 23, 26 (132)   
  
W. succinogenes   
DSM1740 Wild type ATCC 29543 
 
E. coli    
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F' proAB lacIqZΔM15::Tn10 
(Tetr)] 
 
Stratagene 
BN1 ΔeptA ΔlpxT ΔpagP 
 
(8)  
BN2 
 
MKV15b 
 
ΔeptA ΔlpxT ΔpagP ΔlpxM 
 
ΔlpxL ΔlpxM ΔlpxP 
(8)  
 
(133) 
Plasmids   
pET21a Vector containing a T7 promoter; 
ampicillin resistance 
 
Novagen 
jhp0255KO+/- 
 
pET21a containing jhp0255 plus 1000bp 
upstream and 1000bp downstream, with 
jhp0255 coding sequence replaced with 
kanamycin resistance cassette 
 
This work 
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pWSK29 
 
Low copy vector containing T7 and T3 
RNA polymerase promoters; ampicillin 
resistance 
(133)    
  
 
pWSK29jhp0255 
 
 
pWSK29 containing jhp0255 coding 
sequence plus ribosome binding site for 
expression in E. coli 
 
 
This work 
pWSK29cjj81176_0482 pWSK29 containing cjj81176_0482 coding 
sequence plus ribosome binding site for 
expression in E. coli 
 
This work 
pWSK29ws1775 
 
pWSK29 containing ws1775 coding 
sequence plus ribosome binding site for 
expression in E. coli 
 
This work 
pET0634comp pET21a containing hp0954 (rdxA locus) 
with flanking regions; hp0954 coding 
sequence is replaced by jhp0634; used as 
template plasmid for complementation at 
rdxA locus  
 
(22)  
pET0634compjhp0255 
 
pET0634comp containing jhp0255 instead 
of jhp0634 interrupting rdxA locus 
 
This work 
Table 5.1 (continued) 
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Table 5.2: Oligonucleotides used in Chapter 2 
Primer Name Sequence (restriction site) Restriction Site 
1 Fjhp0255+upNheI GCGCGCGCTAGCGCACATTA
TTTAAAGGCTTGTATT 
NheI 
2 Rjhp0255+downXhoI GCGCGCCTCGAGTATTTAGCT
CTTGGCTCAATGTAA 
XhoI 
3 RipKOjhp0255BamHI GCGCGCGGATCCTTAGTTGCC
TTTAGTGGTTGCCAT 
BamHI 
4 FipKOjhp0255NotI GCGCGCGCGGCCGCGGGTTT
GAAGAATCTCAAAGGGGT 
NotI 
5 FKanRBamHI GCGCGCGGATCCAAGGTTTT
AGAATGCAAGGAACAGTG 
BamHI 
6 RKanRNotI GCGCGCGCGGCCGCGGTACT
AAAACAATTCATCCAGTA 
NotI 
7 Fjhp0255 NdeI GCGCGCCATATGAGCTTAAA
ATTTTTCAGG 
NdeI 
8 Rjhp0255 BamHI GCGCGCGGATCCTTAAGCAC
CCAAACCCCTTTG 
BamHI 
9 F0482+NdeI GCGCGCCATATGCAAAGCGT
ATGGTTTTATAT 
NdeI 
 
10 R0482+SalI GCGCGCGTCGACTCATTCCTT
AAATTGATCAGCTA 
SalI 
11 ws1775F GCGCGCCATATGTTGGCGCTG
GCTATCTTGC 
NdeI 
12 ws1775R GCGCGCGTCGACTCACTCTAT
CTCCTCGGTCATC 
SalI 
13 Fjhp0255BamHI_634comp GCGCGCGGATCCACACCCCA
TAAAGAGCAGGTTTAA 
BamHI 
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14 Rjhp0255EcoRI_634comp GCGCGCGAATCCTTAAGCAC
CCAAACCCCTTTGAGA 
EcoRI 
15 RdxA Forward CGCTTCGTATCTTTATAGCCG - 
16 RdxA Reverse CTAGCTTGATTTTCACCACAG
CCAC 
- 
17 up_0255kanRKO_F AAAAAGGCCATACAGCTTAT
TTAG 
- 
18 down_0255kanRKO_R TAGCACAAAAGATAAAAAAA
TGT 
- 
Table 5.2 (continued) 
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Table 5.3: Bacterial strains and plasmids used in Chapter 3 
Strains Genotype or Description Source or Reference 
W3110 Wild type, F- l- rph-1 INV(rrnD, rrnE) 
1 rph-1 
E. coli genetic 
stock center (Yale) 
W3110 pmrD::kan W3110 containing kanamycin cassette 
at pmrD 
This work 
W3110 pmrD::kan  + 
pmrD 
W3110 pmrD- complemented with 
pWSK29pmrD 
This work 
W3110 phoPQ::cam W3110 containing chloramphenicol 
cassette at phoPQ 
This work 
W3110 phoPQ::cam, 
pmrD::kan 
W3110 phoPQ- containing kanamycin 
cassette at pmrD 
This work 
W3110 phoPQ::cam,  
pmrD::kan + pmrD 
W3110 phoPQpmrD- expressing 
pWSK29pmrD 
This work 
W3110 ΔpmrA W3110 with pmrA deleted, no marker This work 
W3110 ΔpmrA  + 
pmrD 
W3110 pmrA- expressing 
pWSK29pmrD 
This work 
MG1655 F-, lambda-, rph-1 Gift from S. Payne 
MG1655 pmrD::kan MG1655 containing kanamycin 
cassette at pmrD 
This work 
MG1655 pmrD::kan 
+ pmrD 
MG1655 pmrD- complemented with 
pWSK29pmrD 
This work 
WD101 W3110 constitutive pmrA mutant, 
polymyxin B resistant 
(63)    
EHEC EDL 933 Serotype O157:H7 ATCC 
ETEC H10407 Serotype O78:H11 ATCC 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F' proAB 
lacIqZΔM15::Tn10 (Tetr)] 
 
Stratagene 
Plasmids   
pET21a Vector containing a T7 promoter; Amp 
resistance 
Novagen 
pET21apmrD pET21a containing W3110 pmrD 
coding sequence 
This work 
pWSK29 
 
Low copy vector containing T7 and T3 
RNA polymerase promoters; Amp 
resistance 
(134) M 
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pWSK29pmrD 
 
pWSK29 containing W3110 pmrD 
coding sequence plus ribosome binding 
site  
This work 
pWSK29EHECpmrD pWSK29 containing EHEC pmrD 
coding sequence plus ribosome binding 
site  
This work 
pWSK29ETECpmrD pWSK29 containing ETEC pmrD 
coding sequence plus ribosome binding 
site  
This work 
Table 5.3 (continued) 
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Table 5.4: Oligonucleotides used in Chapter 3 
 
Primer Sequence (restriction site) 
Restriction 
Site 
1 ECpmrDF_NdeI GCGCGCCATATGGAATGGCTGGTCAA
AAAA NdeI 
2 ECpmrDR_BamHI GCGCGCGGATCCTTACTGAGTTTTCCC
TGC BamHI 
3 pmrDkeiocheck_R GAGTGGGTGCAACGTCAGCAA 
- 
4 pmrAkeiocheck_R 
 
GCTGCGGATGATATTCTGCAA 
- 
5 pmrBkeiocheck_R TTTGGCTATATGCTGGTCGCG 
- 
6 k1 (128)     CAGTCATAGCCGAATAGCCT 
- 
7 GyrBF ACGCTGCTGTTGACCTTCTT 
- 
8 GyrBR TCCTGCTTGCCTTTCTTCAC 
- 
9 PmrDF ATGGAATGGCTGGTCAAAAA 
- 
10 PmrDR CATTCTGCAAAGGCGAGAGT 
 - 
11 EptAF CAGCGACTGGCAAATCT 
- 
12 EptAR TAGTTTCACGCGGGTAGC 
- 
13 PmrAF GGGCGGTGAAGAGTTGATT 
- 
14 PmrAR TTGGTCGAGGGTTCATTGTC 
 - 
15 ArnTF TCAGCCAAGCCGCTATATTC 
- 
16 ArnTR ATCACCGCTGACAAATCTCC 
- 
17 RstAF GTGGAAGATGATGCGGAAGT 
- 
18 RstAR CCTGGTAGCATGATGTCGAGT 
 - 
19 PhoP1 ATAATCGCGTTACACTATTTTAATAAT
TAAGACAGGGAGAAATAAAAATGTGT
AGGCTGGAGCTGCTTCG 
- 
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20 PhoQP2 TTAACGTAATGCGTGAAGTATGGGCA
TATTTATTCATCTTTCGGCGCAGAATG
GGAATTAGCCATGGTCC  
- 
Table 5.4 (continued) 
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